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ABSTRACT  
Marijuana, also called Cannabis, is the illicit drug most frequently used by human adolescents; 
this is facilitated by the fact that users generally perceive these drugs as relatively harmless.  
Recent data estimate that cannabis use starts in the period from 12 to 18 years of age, though 
even earlier use (9–10 years) is now anecdotally reported. Among the many consequences 
related to the cannabis use, it is increasingly emerging as the Δ9-THC, as well as endogenous 
cannabinoids, are able to affect certain functions of the immune system. 
In fact, studies conducted in experimental animals indicate that cannabis impairs the immune 
response by altering the homeostasis of the immune system. 
The adolescence is a particularly vulnerable period of individual life, both for physical and 
psychological maturity; also the immune system during this development period might be 
particularly vulnerable to the effects induced by this drug. However, there aren't currently 
available studies to investigate whether the cannabis intake during adolescence period can have 
a negative impact on some immune functions such as the individual's response to infection, 
allergic and autoimmune pathologies, both during the period of drug intake and in adulthood, 
thus long time from the last direct cannabis exposure. 
The purpose of this study was to investigate whether the use of cannabis during adolescence 
may induce immediate and delayed effects on the immune system that may then persist in 
adulthood. 
As immune parameters we considered both innate and acquired immunity, measuring T-cells 
and macrophage cytokines production.  
We used Balb C/J male mice, 33 post natal days (PND) as model of adolescence age and 80 
PND as model of adult age. Δ9-THC was administerd with increasing subcutaneous (s.c.) doses, 
starting from 5 mg/kg and gradually reaching 15mg/kg in 10 days.  
Control animals were treated with the vehicle for the same duration of time.  
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Some groups of animals were sacrificed, for the immune evaluation, immediately at the end of 
the treatment, while other groups of mice were housed until 90 PND before the immune 
evaluation. 
We recently added a fourth study group consisting of adult animals treated with the drug, for 10 
days, and housed for 47 days, up to 137 PND, when the evaluation of immune parameters were 
performed. The data regarding this last study group are not completed, due to the long times 
required for the implementation of the experimental protocol and refer only to the innate and 
acquired immunity. 
In order to study acquired immunity, young and adult mice were immunized with KLH protein 
to induce an antigen-specific reaction and Th1/Th2 balance was assessed by measuring the 
production of IFN-γ, IL-4 and IL-10 by splenic lymphocytes. 
In order to assess macrophage function we used peritoneal macrophages stimulated in vitro 
with LPS endotoxin; IL-1β and TNF-α were assessed as pro-inflammatory cytokines, while IL-
10 was evaluated as anti-inflammatory cytokine. 
The cytokine production was measured by specific ELISA and Real-Time PCR. 
At the end of Δ9-THC treatment in both young and adult mice, after immunization, a significant 
reduction in the production of IFN-γ was observed, while the Th2 cytokines IL-4 and IL-10 
were significantly increased.  
When we measured immune response of adult mice treated with the drug in adolescence, we 
observed that the production of IFN-γ was still lower and that, in contrast to what observed 
immediately at the end of treatment, also the Th2 cytokine levels were decreased compared 
with vehicle mice.  
In adult animals, assessed 47 days after the end of treatment, there were no significant 
differences between Δ9-THC or vehicle groups.  
  
8 
We also evaluated the ability of the animals to develop an antibody response by measuring IgM 
anti-KLH titers in the serum; in all study groups, the antibody titers were significantly reduced 
compared to the vehicle. 
Regarding the macrophage function, the Δ9-THC treatment induced in both young and adult 
mice a significant increase of IL-10 while TNF-α and IL-1β are decreased. Particularly 
interesting were the results obtained in mice treated in adolescent age with Δ9-THC respect to 
vehicle; in fact, we observed an opposite effect since IL-1β and TNF-α levels were significantly 
increased while IL-10 production was lower, indicating a switch towards a pro-inflammatory 
phenotype of the macrophage.  
These effects on cytokines are at transcriptional level since we observed similar result by 
measuring IL-10, IL-1β and TNF-α mRNA with RT-PCR. In adult animals evaluated 47 days 
after the end of treatment, by analyzing the pro- and anti-inflammatory cytokine levels and their 
relative mRNA expression, no significant differences were found between treatments 
considered. In order to understand whether the Δ9-THC effects might be due to an alteration of 
circulating hormones, we also assessed the modulation of hypothalamic-pituitary-adrenal axis 
(HPA) axis activity, after sub-acute and chronic Δ9-THC treatment, by measuring the 
corticosterone plasma levels in the three study groups.  
The corticosterone concentrations were lower in all groups, indicating a long lasting 
dysregulation of HPA. 
Using a method HPLC/ Mass Spectrometry, we also evaluated blood levels of Δ9-THC and its 
main metabolites in the experimental groups considered, showing that at the end of 10 days 
treatment they were comparable to those that can be found in human heavy smokers. We also 
demonstrated that in animals treated as adolescents and studied as adults, plasma Δ9-THC was 
not more present, further assuring that the effects observed were due to a long lasting 
modulation of immunity     
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In addition, to understand the mechanisms underlying the observed effects, we began to 
investigate whether the Δ9-THC treatment may affect hematopoietic cells development.  
Preliminary data obtained by evaluating the number of colonies formed by hematopoietic 
precursors have not highlighted differences between the different treatment groups.  
Finally, we started to study also the Δ9-THC effects on neuroinflammation, by evaluating the 
basal production of pro- and anti-inflammatory cytokines in brain areas that are particularly rich 
in cannabinoid receptors, such as hippocampus and hypothalamus. 
Our data indicate that chronic treatment with the drug is able to reduce the basal levels of IL-1β 
and TNF-α in the brain areas considered, in adolescent and adult mice assessed immediately at 
the end of treatment.  
The basal production of IL-10 instead appears to be increased compared to relative vehicles in 
mice evaluated immediately at the end of the treatment. 
In adult animals, treated with the drug as adolescents, the basal production of pro-inflammatory 
cytokines, in hypothalamus and in hippocampus, appears to be increased with respect to 
vehicles and IL-10 decreased, indicating a predisposition to a pro-inflammatory status.  
Although these data are preliminary they indicate a parallel modulation of brain and peripheral 
cytokines by Δ9-THC. 
In conclusion, these results indicate that the immune system is profoundly altered by treatments 
with Δ9-THC, with the presence of a dysregulated response. 
In particular we can affirm that the administration of Δ9-THC in adolescent animals has 
significant effects on the immune response that last long after its intake. 
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INTRODUCTION 
HISTORY OF CANNABIS  
The cannabis plant has been known since antiquity and  grows  in  almost  all  parts  of  the  
world,  but  has  been known principally as a source of useful fibre for the manufacture  of  
textiles  and  rope. The use of the plant has origins in Asia, in particular in China, where 
archaeological and historical findings indicate that Cannabis was cultivated for fibres since 
4000 B.C. 
Kalant (Kalant, 2001) and Zuardi (Zuardi, 2006) have reported also an important use of 
cannabis in Asia for the treatment of disorders like rheumatic pain, intestinal constipation, 
disorders of the female reproductive system, malaria and others.  
In India the use of cannabis was disseminated, both as a medicine and recreational drug, 
probably around 1000 B.C. (Zuardi, 2006). From Asia, cannabis spread to the Western World 
where several references reported the use of this plant in Ancient Egypt (Figure 1). 
 
Figure 1 Map showing the countries of origin Cannabis indica and sativa. Figure taken from Hilling 2005 
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The scarce literary references regarding the use of cannabis by the Greeks and Romans suggest 
that it was little used by these populations. 
In Africa the use of cannabis began around the 15th century where it was reported useful for 
snake bite, to facilitate childbirth, malaria, fever, asthma and dysentery. In the 16th century, 
Cannabis reached the Americas, where probably African slaves brought the plant’s seeds to 
Brazil. Here, cannabis was above all used in popular religious rituals. In the middle of 19th 
century, cannabis was introduced in Western Medicine by O'Shaughnessy, an Irish physician, 
and Moreau, a French psychiatrist.  
Their contributions had a deep impact on Western medicine, especially due to the scarcity of 
therapeutic options for infectious diseases (Zuardi, 2006). 
In the 20th century, several laboratories started to market cannabis extracts or tinctures, such as 
Merk, Burroughs-Wellcome, Parke-Davis and Eli Lilly (Fankhauser, 2002). 
During this period, the medical indications of cannabis, as reported in Sajous’s Analytic 
Cyclopaedia of Practical Medicine (1924)(Aldrich, 1997), were summarized in three areas: 
sedative or hypnotic, analgesic and in appetite and digestion dysfunctions. 
After this period, the use of cannabis significantly decreased, because of the difficulty to obtain 
replicable effects, due to the varying efficacy of different samples of the plant. 
Moreover, the introduction of many legal restrictions limited the medicinal use and 
experimentation with cannabis. In the second half of 20th century, cannabis was mainly used as 
a drug for recreational use by intellectuals groups, and later spread among the younger 
generation throughout the Western World. 
In 1964, Gaoni (Gaoni, 1964) isolated and characterized the main psychoactive component of 
cannabis, Δ9-tetrahydrocannabinol, thus contributing to a proliferation of studies about the 
active components of the plant.  
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In the last 30 years three drugs have been developed from cannabis or on the basis of active 
components derived from cannabis: 
1. Nabilone, synthetic analogue of Δ9-THC; it is used for suppression of nausea and 
vomiting produced by chemotherapy. 
2. Dronabinol; it is the synthetic (-)-trans-Δ9-tetrahydrocannabinol; this drug finds 
applications as an anti-emetic and appetite stimulant. 
3. Sativex®; it contains equal amounts of Δ9-THC and the non-psychoactive plant 
cannabinoid, cannabidiol (CBD), and is prescribed for the symptomatic relief of 
spasticity and neuropathic pain in adults with multiple sclerosis, and as an adjunctive 
analgesic treatment in advanced cancer (Pertwee, 2009). 
Cannabis is currently the most recreationally used illicit substance across the globe; the 
prevalence of use has increased markedly over the past decade in young people in the Europe 
although patterns of consumption vary between different social groups.  
TAXONOMY OF CANNABIS  
Cannabis sativa is an annual, dioecious, wind-pollinated herb, with male and female flowers 
developing on separate plants. It propagates from seed, grows in open sunny environments with 
well drained soils and has an abundant need for nutrients and water. It can reach up to 5 meters 
in height in a 4-6 month growing season. 
According to current botanical classification, Cannabis belongs, with Humulus (hops), to the 
family of Cannabinaceae (also Cannabaceae or Cannabidaceae).  
As regards the exact taxonomy of the genus Cannabis (family Cannabaceae) there are different 
opinions depending on considering the polytypic or monotypic species.  
The binomial nomenclature (Linnaeus, 1735; Small, 1976) considers this genre as monotypic, 
the only species known as Cannabis sativa L. 
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In 1785 Lamarck described a second species of Cannabis, which he called Cannabis indica 
Lam.: this species, of lesser importance than the Cannabis sativa as a fiber plant, shows a more 
substantial stimolant use. With the name of Cannabis indica it joined Pharmacopoeia of many 
countries, thus indicating the species designated for medicinal preparations.  
In 1924 the Russian botanist Janichevsky described a third species, which he identified as 
Cannabis ruderalis; this species extended from the north of European Russia to Central Asia 
(Schultes, 1976). 
In 1976, Small in his taxonomic revision defined a single species of Cannabis with two 
subspecies: C. sativa L. subsp. sativa, and C. sativa L. subsp. Indica. 
 
 
 
 
Figure 2 Morphology of Cannabis species 
The hypothesis was that the two subspecies differentiated substantially as a result of selection 
by man: the Cannabis sativa subsp. Sativa was selected for the production of fiber or seeds, 
while Cannabis ativa subsp indica had been selected for medical and stimolant use. 
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Taxonomic studies conducted in the same year led the botanist Schultes to identify, on the basis 
of morphological differences, at least three species, Cannabis sativa, Cannabis indica, and 
Cannabis ruderalis so rejecting monotypic theories (Schultes, 1976).  
The traditional forms in which the substance is consumed are: Marijuana (inflorescences, dried 
leaves), in which the percentage of Δ9-THC can vary between 0.5 and 5% in seedless varieties 
and between 7 and 14% in seeded varieties, called "sinsemilla", while even higher 
concentrations are reported for the “Nederweed marijuana”; Hashish (cannabis resin and 
pressed flowers) with Δ9-THC concentrations ranging from 2 to 20%, Hashish oil at 
concentrations of 15-50%.  
Cannabis is smoked in special devices (chilum, hookah) or hand-rolled cigarettes (joints, canes, 
joint) with or without the addition of tobacco. 
CANNABIS COSTITUENS 
Cannabis is composed by a vast number of compounds (approximately 538), including mono- 
and sesquiterpenes, sugars, hydrocarbons, steroids, flavonoids, nitrogenous compounds and 
amino acids, among others. The more known and the most specific class of cannabis 
constituents is represented by cannabinoids, which are characterized by a C21 terpenophenolic 
constituent’s structure (ElSohly and Slade, 2005). There are ten main types of cannabinoids and 
fourteen different cannabinoids subtypes, based on their chemical structure (Figure 3). 
The first natural cannabinoid to be discovered was cannabinol (CBN), which was extracted in 
1899 and chemically characterized in 1940 (Adams et al., 1940).  
In 1963, Mechoulam’s group isolated cannabidiol (CBD), the main non-psychoactive 
constituent of cannabis (Mechoulam and Shvo, 1963), and one year later they isolated and 
characterized Δ9-THC, the main psychoactive component of cannabis (Gaoni, 1964). In more 
recent years, other phytocannabinoids have been isolated and characterized, but it is possible 
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that some of them may not have been discovered yet. 
Phytocannabinoids are synthesised in cannabis by glandular trichomes as carboxylic acids from 
geranyl pyrophosphate and olivetolic acid to yield the parent phytocannabinoid compound, 
cannabigerolic acid (CBGA). Subsequent reactions involving different enzymes catalyze the 
transformation of CBGA into other phytocannabinoids. The presence of these enzymes differs 
between various strains and species of cannabis, resulting in a different content of 
phytocannabinoids (Russo, 2007). 
 
 
 
Figure 3 The phytocannabinoids can be subclassified into 10 main groups depending on their chemical structure. 
Figure taken from Hanus, 2009 
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Δ9-TETRAHYDROCANNABINOL (Δ9-THC) 
Δ9-THC is the main psychoactive constituent of cannabis; chemically, Δ9-THC is a poorly 
water soluble, amorphous substance which is sticky, resin-like and highly viscous which makes 
it difficult to handle and process (Thumma et al., 2008).  
As a cannabis constituent, Δ9-THC is assumed to be involved in self-defence, perhaps against 
herbivores. Besides, Δ9-THC has been found to posses high UV-B (280-315 nm) absorption 
properties, which have been speculated to protect the plant from harmful UV radiation exposure 
(Pate, 1994). 
 
 
Figure 4 The molecur structure of Δ9-THC 
Dronabinol is the synthetic analogue of tetrahydrocannabinol, in particular the (-)-trans-Δ9-
tetrahydrocannabinol isomer that is the main isomer of as a cannabis constituent, (Pate, 1994). 
Dronabinol is sold as Marinol (a registered trademark of Saolvay Pharmaceuticals); in this 
formulation, the drug has limited stability and has to be stored at low temperatures (4°C). 
Furthermore, Δ9-THC has been reported to be unstable in acid solutions or when exposed to 
heat, air, and light. Hence, in the last few years researchers have been challenging the 
development of Δ9-THC as a prodrug, to avoid the pharmacokinetics and physico-chemical 
limitation properties of the pure drug (Thumma et al., 2008).   
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PHARMACOKINETICS OF Δ9-THC 
ABSORPTION 
Smoking is the principal route of cannabis administration and provides a rapid and higly 
efficient method of drug delivery. Approximately 30% of Δ9-THC in marijuana or hashish 
cigarettes is destroyed by pyrolysis during smoking (Abrams et al., 1985). 
Smoked drugs are highly abused in part because of the efficiency and speed of delivery of the 
drug from the lungs to the brain.  
Bioavailability of smoked Δ9-THC is reported to be 18%-50% partly as a result of the intra- and 
inter-subject variability in smoking dynamics that contribute to uncertainty in dose delivery 
(Agurell et al., 1986).  
The number, duration, and spacing of puffs, hold time, and inhalation volume greatly influence 
the degree of drug exposure (Azolorosa et al., 1992). Δ9-THC can be measured in the plasma 
within seconds after inhalation of the first puff of marijuana smoke. 
In some studies Δ9-THC was measured in blood, and expected values were found to be about 
half those of plasma. Albumin and other proteins that bind Δ9-THC and the poor penetration of 
Δ9-THC into red blood cells contribute to these higher plasma concentrations. 
If cannabis is ingested orally, absorption is slower and peak plasma Δ9-THC concentrations are 
lower (Law et al., 1984).  
Wall et al. (1983) found peak Δ9-THC concentrations approximate 4-6 hours after ingestion of 
15-20 mg of Δ9-THC in a chocolate cookie. Oral bioavaialability has been reported to be 4-
20%, in part as a result of degradation of drug in the stomach.  
Also, there is significant first-pass metabolism to active 11-hydroxy-Δ9-tetrahydrocannabinol 
(11-0H-THC) and inactive metabolites. Plasma 11-OH-THC concentrations range from 50 to 
100% of Δ9-THC concentrations following the oral route of cannabis administration compared 
to only about 10% after smoking (Wall et al., 1983).  
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11-OH-THC is equipotent to Δ9-THC, explaining the fact that pharmacodynamic effects after 
oral cannabis administration appear to be greater that those after smoking Δ9-THC at the same 
concentrations. 
DISTRIBUTION 
Cannabinoids rapidly penetrate into the tissues (liver, heart, lung, gut, kidney, spleen, 
mammary gland, placenta, adrenal cortex, thyroid, pituitary gland, fat and lower concentrations 
in brain, testis and foetus) because of their high lipophilicity. Therefore, the distribution volume 
is about 10 L/kg (Kelly and Jones, 1992). Δ9-THC is strongly bound to plasma proteins (~97%). 
About 60% is bound to lipoproteins (the low-density fraction), about 9% to blood cells and the 
rest to albumin. The Δ9-THC metabolite 11-hydroxy-Δ9-THC (11-OH-THC) is even more 
strongly bound (~99%). 
METABOLISM 
About 100 metabolites have been identified for Δ9-THC so far. All cannabinoids are good 
substrates of cytochrome P450. The hydroxylation sides of Δ9-THC are at C11 and C8 as well 
as at all positions of the alkyl side-chain. The preferred hydroxylation site in man is C11. It has 
been shown that cytochrome P450 isoenzyme 2C9 catalysis the formation of the psychoactive 
11-OH-THC metabolite of Δ9-THC and that cytochrome P450 3A is responsible for the 
hydroxylation at the 8β-position (Watanabe et al., 1995).  
Many of the hydroxyl groups undergo further oxidation after the hydroxylation.  
Carboxylic groups at C11 and C5’ (alkyl side-chain) are formed. 11-OH-THC is further 
oxidised, probably by alcohol dehydrogenase and of microsomal alcohol oxygenase, to the 
intermediate aldehyde 11-oxo-THC followed by oxidation to 11-nor-9-carboxy-THC catalysed 
by a microsomal aldehyde oxygenase, a member of the CYP2C subfamily (Watanabe et al., 
1995; Nadulski et al., 2005)  
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After glucuronidation of the carboxy group, the THC-COOH is the main metabolite excreted 
and found in urine (Maurer et al., 2006).  
Carbon atoms from the alkyl side-chain get lost after β-oxidation and related reactions of the 
C5’-acid. The predominant phase II metabolite of Δ9-THC is the O-ester-glucuronide of THC-
COOH. The formation of conjugates with long-chain fatty acids is another possible pathway. 
Although it is a phase II reaction, the lipophilicity is rather increased than decreased. It is 
possible that these conjugates with long-chain fatty acids may be retained within tissues for 
considerable periods of time because they are membrane constituents resembling compounds. 
 
 
Figure 5 The metabolism of Δ9-THC 
ELIMINATION  
Elimination of Δ9-THC from the plasma is rather slow because of the limited re-diffusion of Δ9-
THC from body fat and other tissues into the blood. The results of this phenomenon are low 
plasma levels. The literature describes very variable half-life periods from 1 to 4 days. The 
absolute elimination time could require up to five weeks. Δ9-THC metabolites are excreted in 
urine (~20%) and faeces (~80%). The distinctive enterohepatic cycle is another reason for the 
slow elimination (Kelly and Jones, 1992). 
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Most urinary metabolites are acids. The major metabolites found in urine are THC-COOH and 
THC-COOH-glucuronide.  
Normalised to the drug creatinine ratio, THC-COOH and its glucuronide are used for detection 
and monitoring of drug abuse (Musshoff and Madea, 2006). 
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THE ENDOCANNABINOID SYSTEM 
The endocannabinoid system refers to a group of endogenous lipid and their receptors that are 
involved in a variety of physiological process including neurotransmitter release, synaptic 
plasticity, inflammation and appetite stimulation. The endocannabinoid system is constitued by: 
• The cannabinoid receptor type 1 and 2, (CB1 and CB2), primarily located in the Central 
Nervous System (CNS) and periphery respectively 
• The endogenous lipids (endocannabinoids) that are synthesized “ on demand” as ligands 
for the cannabinoid receptors 
• Enzymes involved in the synthesis and degradation of endocannabinoids 
CANNABINOID RECEPTORS 
The two main subtypes of cannabinoid receptors (CBR) classically described (CB1 and CB2) 
are G protein coupled receptors, therefore constituted by a single polypeptides with an 
extracellular N-terminus, and intracellular C-terminus and seven transmembrane helices. Both 
mainly activate G proteins (Gi proteins) inhibitory to adenylate cyclase thus inhibiting the 
conversion of ATP to cyclic AMP (cAMP)(Howlett and Mukhopadhyay, 2000).  
However they can also activate adenylate cyclase through stimulating G proteins (Gs proteins), 
and both are positively coupled to mitogen-activated protein kinase (MAPK)(Woelkart et al., 
2008).  
CB1 is coupled with ion channels, inhibiting D-type K+, N and P/Q-type Ca 2+ currents, and 
activating inward and A-type rectifying K+ currents (Croxford and Yamamura, 2005).  
For CB2, the ion channel modulation is more variable; CB2 signaling mechanisms also involve 
the activation of phosphatidylinositol 3-kinase and Akt (PI3-Akt) pathway and increases the 
synthesis of the sphingolipid messenger ceramide, thus having a pro-survival and pro-apoptotic 
effect, respectively (Carracedo et al., 2006).  
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Besides the CB pathway, endocannabinoids also interact with other receptors, like the vanilloid 
receptor-type 1 (TRPV-1) activated by anandamide (AEA), and also K+ channels, 5-HT3 
receptors and alpha 7nicotinic receptors (Mackie, 2008; Oz, 2006).  
It is not clear which of these interactions are relevant for the physiologic effects of 
cannabinoids or just a consequences of their lipophilic character. Some effects of the classical 
cannabinoids such as anti-emesis may not be mediated only by CB1-CB2 receptor system; 
some evidence suggests the existence of additional cannabinoid receptor subtypes possibly 
responsible for these alternative mechanisms (Howlett et al., 2002).  
Recent studies focus on GPR55, suggesting that this receptor can be activated by anandamide 
and 2-arachidonoylglycerol (Ryberg et al., 2007).  
CB1 RECEPTOR 
CB1 is the most abundant G-protein–coupled receptors in brain and was cloned from rat and 
human brain specimens in 1990 and encoded a protein with 472 amino acids. 
It is highly expressed in brain tissue and to a lesser extent in the adrenal gland, reproductive 
organs, bone marrow and immune cells. 
The mouse CB1 sequence has also been cloned, and showed 99% and 97% identity to rat and 
human CB1, respectively, at amino acid level (Bosier et al., 2010). 
CB1 genes have been demonstrated in other species including the tetraodontoid fish, Fugu 
rubripes (Yamaguchi et al., 1996), suggesting the conservation and importance of the CB 
system in evolution (Klein et al., 1998). 
Regarding the receptor signalling, CB1 receptor is coupled to Gi and Go proteins, and its 
activation involves the inhibition of adenylyl cyclase with a consequent decrease in cyclic AMP 
production. Activation of the CB1 receptor is also associated with the activation of MAPK, 
which regulates many cellular functions such as cell growth, transformation and apoptosis. The 
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CB1 receptor has also been associated with the modulation of voltage-gated ion channels, in 
particular N-and P/Q-type calcium channels and inwardly rectifying A-type potassium 
channels, which are thought underlie the cannabinoid-induced inhibition of neurotransmitter 
release at presynaptic level (Howlett et al., 2002). 
CB2 RECEPTOR 
The gene encoding the human cannabinoid CB2 receptor was cloned in 1993 (Munro et al., 
1993) and has now been isolated from several diverse species including mouse (Shire et al., 
1996), rat (Brown et al., 2002), Japanese pufferfish (Elphick, 2002) and zebrafish (Rodriguez-
Martin et al., 2007). In addition this receptor was revealed to exhibit 68% identity to the CB1 
receptor within the transmembrane regions and 44% identity throughout the whole CB1 protein 
(Munro et al., 1993). Unlike the CB1 receptor nucleotide sequence, which appears to be highly 
conserved between the human, mouse and rat, the nucleotide sequence of the CB2 receptor 
exhibits less homology between these mammalian species. For example, the human and mouse 
CB2 receptor share 82% amino acid identity (Shire et al., 1996) whereas the mouse and rat 93% 
homologous (Brown et al., 2002).  
CB2 receptors are prevalently found in immune tissues, most abundantly in the spleen and 
leukocytes (Ofek et al., 2006). At the cellular level, B cells express high levels of CB2 
receptors, while moderate levels are found in natural killer cells, and low levels are found in T-
cells (Galiegue et al. 1995). The presence of CB2 in dendritic cells, potent antigen-presenting 
cells, suggests a role for cannabinoids in modulating antigen presentation (Matias et al., 2002). 
Other tissues and cells also express CB2 receptors including enterocytes, osteoclasts and 
osteoblasts, and the liver (Mackie, 2008). Initially, northern analysis, quantitative Real Time-
PCR analysis and autoradiography could not elicit the CB2 presence in the brain, but Western-
blot analysis and immunohistochemistry demonstrated its presence in astrocytes and microglia. 
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Because CB2 expression on microglia is related to the cell activation status, it was also 
suggested that it may be induced by local inflammation, infection or stress (Croxford and 
Yamamura, 2005), but further studies demonstrated that CB2 is present in astrocytes, microglia, 
neural subpopulations and oligodendroglial progenitors in healthy brains (Van Sickle et al., 
2005). Interestingly, CB2 receptor appears to be highly inducible, which makes this receptor an 
interesting tool for the treatment of diseases such as inflammation, pain, atherosclerosis, hepatic 
fibrosis, and bone remodelling, where CB2 receptors have been shown to be involved (Mackie, 
2008). 
 
Figure 6 Mouse cannabinoid receptor CB1(a) and CB2 (b). Figure taken Klein et al., 1998 
PHARMACOLOGY OF Δ9-THC AT NON-CB1, NON-CB2 RECEPTORS 
It has been found that Δ9-THC interacts with several no cannabinoid receptors, targeting the 
orthosteric or allosteric sites of other GPCRs, transmitter-gated channels, ion channels or 
nuclear receptors. For example, Δ9-THC binds the allosteric sites of opioid receptors. GPR55 is 
an additional GPCR that has been found to be activated by Δ9-THC (Pertwee, 2010). 
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Moreover Δ9-THC acts as a potent antagonist on the ionotropic receptor 5-HT3, which belongs 
to the serotoninergic receptor family. 5-HT3 receptors are located prevalently in the central and 
peripheral neurons, where they trigger rapid depolarization due to the opening of non-selective 
cation channels (Na+, Ca++ influx, K+ efflux) (Hannon and Hoyer, 2008).  
In particular, Δ9-THC has been found to modulate the 3A subunit of the human 5-HT3 receptor.   
Δ9-THC has also been shown to interact with some ion channels, in particular T-type Calcium 
(Cav3) and Potassium Voltage (Kv1.2) channels. Additional Δ9-THC-target receptors are 
Transient Receptor Potential (TRP) channels, which are a family of ion channels with relative 
non-selective permeability for cations, including sodium, calcium and magnesium. In 
particular, Δ9-THC activates both TRP Vanilloid-2 (TRPV2) and TRP Ankirin-1 (TRPA1) 
channels (Pertwee, 2010). 
Finally, Δ9-THC has been shown to interact with PPARγ (O'Sullivan et al., 2006).  
PPARγ, also known as the glitazone receptor, is a nuclear receptor which regulates fatty acid 
storage and glucose metabolism by controlling the expression of specific target genes involved 
in adipogenesis, inflammatory responses, and lipid metabolism. 
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ENDOGENOUS LIGANDS 
The discovery of the cannabinoid receptors suggested the existence of endogenous ligands, 
which could bind to these receptors and exert physiological effects.  
The first endocannabinoid to be isolated was anandamide (arachidonoyl ethanolamide, AEA), 
which is the amide between arachidonic acid and ethanolamine (Devane et al., 1992). This 
finding was soon to be followed by the identification of 2-arachidonoylglycerol (2-AG), the 
arachidonate ester of glycerol (Mechoulam et al., 1995). More recently came the discovery of 
other endocannabinoids, 2-arachidonyl-glycerol ether (noladin ether), N-arachidonoyl-
dopamine (NADA). These lipid compounds differ totally in structure from Δ9-THC, the main 
exogenous cannabinoid.  
Endocannabinoids are considered either neurotransmitters or neuromodulators: they have 
distinct synthetic pathway, are released from cells upon depolarization and calcium entry, and 
their synaptic action is rapidly terminated by reuptake and intracellular enzymatic degradation. 
AEA and 2-AG are produced from cleavage of two different phospholipid precursors present in 
the cell membranes of neurons and immune cells in particular. AEA is synthesized from the 
membrane phospholipid N-arachidonoyl phosphatidylethanolamine by a phosphodiesterase 
called phospholipase D, an enzyme stimulated by depolarization-induced increase in 
intracellular Ca2+. The synthetic pathway is also indirectly stimulated by cAMP/protein kinase 
A, indicating possible receptor-mediated mechanism. The synthesis of 2-AG is also calcium-
dependent. An interesting feature of AEA and 2-AG is the “on-demand” synthesis and release 
of these lipids, differentiating the endocannabinoids from classical neurotransmitters-hence the 
term “modulator”.  
AEA is then known to be transported into cells by carrier-mediated uptake, which does not 
depend on sodium or adenosine-5’-triphosphate (ATP), another difference from classical 
neurotransmitters, but similar to the structurally related prostaglandin E2.  
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Both AEA and 2-AG are known to be rapidly hydrolyzed by the intracellular enzyme fatty acid 
amide hydrolase (FAAH).  
Endocannabinoids may function physiologically as retrograde synaptic messengers.  
When a postsynaptic neuron is strongly depolarized, it synthesizes and releases 
endocannabinoids through a non-vesicular mechanism. These molecules, in turn, bind the 
presynaptic neuron at CB1 receptors and inhibit its neurotransmitter release. It is a form of 
negative feedback. The chemical nature of the presynaptic neuron is important. If the release of 
an inhibitory transmitter like γ-aminobutyric acid (GABA) is decreased, it is called in 
electrophysiology depolarization-induced suppression of inhibition (DSI) and would result in 
exacerbation of postsynaptic transmission.  
If the release of an excitatory neurotransmitter like glutamate is decreased, it is referred to as 
depolarization-induced suppression of excitation (DSE), and diminishes postsynaptic 
transmission (Di Marzo, 2008). Both DSI and DSE depend on rises in calcium and Gi proteins, 
which are also necessary for the synthesis and release of endogenous cannabinoids and a 
feature of their receptors. Furthermore, CB1 stimulation inhibits GABA release from 
hippocampal interneurons and glutamate from cerebellar basket cells (which synapse with 
Purkinje neurons) (Di Marzo, 2008). 
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IMMUNE SYSTEM  
The resistance to diseases, in particular infectious diseases is defined as immunity.  
The set of cells, tissues and molecules that mediate such resistance takes the name of the 
immune system and the sequence of reactions that occur as a result of the meeting of these cells 
and molecules with infectious antigens is called the immune response. 
The physiological function of the immune system is to prevent infections and eradicate once 
they are established in the body.  
The defense mechanisms of the host on which it relies include innate and acquired immunity. 
Innate immunity is involved in an initial protection against infection and is in constant 
operation in healthy subjects, while acquired immunity develops more slowly and is involved 
the most effective defense against infectious agents. The main characteristics of acquired 
immunity, that better distinguish it from that innate immunity, are represented by the fine 
specificity for antigens and structurally different from the fact of developing memory in respect 
of a previous exposure to the antigen (Parkin and Cohen, 2001). 
Innate immunity puts in place a first line of defense that consists of epithelial barriers, 
specialized cells and substances naturally equipped with power antibiotic, used as blocking the 
penetration of microbes into the tissue. If the pathogens manage to overcome the epithelia, are 
attacked by phagocytes and lymphocytes specialized cells called "natural killer" (NK), as well 
as numerous proteins present or plasma, including those of the complement system. The 
mechanisms of innate immunity are able to identify and respond to the microorganisms, but 
without reacting against foreign substances of non-infectious nature, moreover, these 
mechanisms are programmed to react against different classes of molecules produced by 
microbes and, in addition to providing a first embankment defense against infection, enhance 
immune responses acquired (MacPherson and Austyn, 2012). 
Acquired immunity includes lymphocytes and some of their products, the antibodies. 
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The cells of this class of immunity express receptors that recognize specifically the products of 
the different microbes, as well as non-infectious molecules (antigens). The answers acquired 
will not start unless the microbes or antigens, derived from them, exceed epithelial barriers and 
make contact with the lymphocytes. There are two types of acquired immunity: humoral 
immunity and cellular immunity (or cell-mediated), they are based on the intervention of 
different cells and molecules, and are members of the defense, respectively, toward microbes 
extracellular and intracellular microbes. More precisely, the humoral immunity is mediated by 
antibodies produced by B-lymphocytes. These molecules are released into the circulation and 
mucosal secretions do and work to neutralize and eliminate microbes and microbial toxins in 
the blood and into the lumen of equipment, such as the gastro-intestinal tract and the respiratory 
system (MacPherson and Austyn, 2012). 
Therefore, the antibodies are essential in preventing the penetration of foreign pathogens in the 
body and preventing the colonization of cells and connective tissues of the host. 
Cellular immunity, however, rests on the intervention of cells called T-lymphocytes. 
Some T-lymphocytes activate the phagocytes to destroy microorganisms, while others directly 
kill host cells in which there is the infectious agent. 
T AND B LYMPHOCYTES 
A key role is played, in the immune system, by the CD4 + helper T-cells, which mediate the 
immune response, both humoral and cell-mediated immunity. 
The T-lymphocyte response to microbial antigens comprises a series of successive stages, that 
induce their numerical expansion and processing of virgin T-cells in effector cells.  
The virgin T-lymphocytes express the TCR (T-cell receptor for the peptide-MHC complexes) 
and other molecules, forming the device for the recognition of the antigen, that promotes the 
differentiation of T-cells into effector cells (Abbas et al., 2003).  
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Simultaneously with the antigenic recognition, they receive further signals by microbes or 
products of the innate response, which induce the secretion of proteins called cytokines. Then, 
part of the activated lymphocytes undergoes differentiation, transforming into cells capable of 
eradicating pathogens strangers. The CD4 + T-helper lymphocytes can differentiate into 
subpopulations of effector cells, which produce a spectrum of different cytokines, equipped 
with various functions. The subpopulations of T-helper cells best characterized are called Th-1 
and Th-2. Th-1 cells potentiate the killing of microorganisms mediated by phagocytic cells, 
producing IFN-γ. This protein is a potent activator of macrophages and stimulates the 
production of antibodies of an isotype that promotes phagocytosis, in addition to stimulating the 
expression of MHC (major histocompatibility complex) class II and macrophages. They also 
produce IL-2, a cytokine essential for their activation and subsequent clonal expansion.  
Th-2 cells promote, instead, a type of immune response mediated by eosinophils and 
independently by phagocytes, producing IL-4, which stimulates the production of IgE 
antibodies (Abbas et al., 2003). 
Among the cytokines produced by lymphocytes Th-2 there is also the IL-10, which has an 
important role in inhibiting of activating macrophage and therefore in the suppression of the 
responses mediated by Th-1 cells. The differentiation in cells Th-1 and Th-2 is a process finely 
regulated by stimuli that T-lymphocytes virgin receive when they encounter microbial antigens. 
B-lymphocytes instead develop and mature in the bone marrow, where through appropriate 
rearrangements develop numerous variants of B-cell receptors (BCR). These structures 
constitute the membrane precursors of future antibodies (which are also released in soluble 
form by plasma cells) and as these recognize antigens in the native form.  
Selection mechanisms of B-lymphocytes are little known, although it is clear that it is a process 
less rigid than that of T-lymphocytes (MacPherson and Austyn, 2012). 
This phenomenon can be explained by two reasons: 
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• B-lymphocytes depend on the interaction with the CD4+ T-lymphocytes for their 
activation in plasma cells. So if a B-lymphocyte is self-reactive, but is not triggered by 
T-lymphocyte, can not be activated and give autoimmunity. 
• B-lymphocytes can recognize a much larger number of non-peptide antigens. So a rigid 
elimination of all self-reactive clones could restrict the antibody response in the event of 
aggression (Abbas et al., 2003). 
CYTOKINES 
The body's defense against foreign organisms is mediated by an innate immune response and an 
acquired immune response: the effector phase of both types of immune response is largely 
mediated by proteins called cytokines. These are a heterogeneous group of soluble proteins 
involved in intracellular transduction signal (Borish and Steinke, 2003). Although the cytokines 
are a family of proteins very different between them, these molecules have common 
characteristics:  
• they are produced during the effector phase of both the innate and the acquired  
immunity and serve to mediate and regulate immune and inflammatory responses.  In 
the Innate immunity, microbial products such as LPS directly stimulate mononuclear 
phagocytes to secrete cytokines, while cytokines derived from T-cells are above all 
produced in response to specific recognition of foreign antigen 
• the secretion of cytokines is a phenomenon of short duration and auto-limited 
• several cytokines are produced by many different cell type 
• cytokine acts on many different cell types: this characteristic is defined pleiotropism 
• often perform many different effects on the same target cells 
• their activity is often redundant 
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• cytokines often influence the synthesis of other cytokines, and their interaction can have 
an  antagonistic, additive or synergistic effect 
• the action of cytokines may be autocrine, paracrine and endocrine 
• the expression of many cytokine receptors is regulated by specific signals, constituted 
by other cytokines or from the same, which  binding  its receptor, generates 
amplification  or inhibition circuits 
On the basis of the function, the cytokines can be divided into 4 groups: 
1. mediators of innate immunity products from mononuclear phagocytes 
2. activators of growth and differentiation of lymphocyte, produced in consequence of the 
antigenic recognition by T-lymphocytes 
3. regulators of immune-mediated inflammation, which activate inflammatory cells evoked 
as a result of non-specific antigenic recognition of T-lymphocytes 
4. substances having a stimulant growth and differentiation action of immature leukocyte, 
derived from lymphocytes and other non-lymphoid cells 
CYTOKINES THAT MEDIATE AND REGULATE INNATE IMMUNITY 
TNF-α 
This proinflammatory cytokine was first isolated in 1975, and its name is misleading in that it 
does not cause the necrosis of all tumors.  
As a matter of fact, it may stimulate the growth of some tumors.  
TNF-α is a 185-amino-acid glycoprotein, which is cleaved from a 212-amino-acid peptide, and 
the cleavage occurs on the cell surface of mononuclear phagocytes. The major cell source of 
TNF-α is the macrophage, specifically the endotoxin-activated mononuclear phagocyte. Other 
sources include endothelium after tissue damage, antigen-stimulated T-cells, activated NK cells 
and activated mast cells. IFN-γ augments TNF-α synthesis.  
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TNF-α is a mediator of both natural and acquired immunity (Borish and Steinke, 2003).  
TNF-α induces the production of IL-1, IL-6, TNF-α itself and chemokines via stimulation of 
macrophages. It exerts an IFN-like protective effect against viruses and augments expression of 
MHC class I molecules. TNF-α is an endogenous pyrogen that acts on cells in hypothalamic 
regulatory regions of the brain to induce fever. It suppresses appetite.  
The hypothalamic–pituitary–adrenal axis (HPA) is stimulated via the release of corticotrophin-
releasing hormone by TNF-α.  
TNF-α suppresses bone marrow stem cell division and reduces tissue perfusion by depressing 
myocardial contractility (Borish and Steinke, 2003). 
IL-1 
Interleukin-1 (IL-1) was originally discovered as a factor that induced fever, caused damage to 
joints and regulated bone marrow cells and lymphocytes, it was given several different names 
by various investigators.  
Later, the presence of two distinct proteins, IL-1α and IL-1β, was confirmed, which belong to a 
family of cytokines, the IL-1 superfamily (Borish and Steinke, 2003).  
IL-1 plays an important role in both innate and adaptive immunity and is a crucial mediator of 
the host inflammatory response in natural immunity. The major cell source of IL-1 is the 
activated mononuclear phagocyte. Other sources include dendritic cells, epithelial cells, 
endothelial cells, B-cells, astrocytes, fibroblasts and Large Granular Lymphocytes (LGL). 
Endotoxins, macrophage-derived cytokines such as TNF-α or IL-1 itself, and contact with 
CD4+ cells trigger IL-1 production.  
IL-1 can be found in circulation following Gram-negative bacterial sepsis. It produces the 
acute-phase response in response to infection. IL-1 induces fever as a result of bacterial and 
viral infections (Dinarello and Wolff, 1993).  
Activation of T-helper cells, resulting in IL-2 secretion, and B-cell activation are mediated by 
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IL-1. It is a stimulator of fibroblast proliferation, which causes wound healing. Autoimmune 
diseases exhibit increased IL-1 concentrations. It suppresses further IL-1 production via an 
increase in the synthesis of PGE2. 
IL-10 
First identified as an inhibitor of IFN-γ synthesis in Th1 cells, IL-10 is an important 
immunoregulatory cytokine. It is an anti-inflammatory cytokine that was first called human 
cytokine synthesis inhibitory factor (Del Prete et al., 1993).  
IL-10 is secreted by macrophages, Th2 cells and mast cells.  
Cytotoxic T cells also release IL-10 to inhibit viral infection- stimulated NK cell activity.  
IL-10 is a 36-kDa dimer composed of two 160-aminoacid residue long chains. Its gene is 
located on chromosome 1 in humans and consists of five exons.  
IL-10 inhibits the synthesis of a number of cytokines involved in the inflammatory process 
including IL-2, IL-3, GM-CSF, TNF-α and IFN-γ.  Based on its cytokine-suppressing profile, it 
also functions as an inhibitor of Th1 cells and by virtue of inhibiting macrophages, it functions 
as an inhibitor of antigen presentation. Interestingly, IL-10 can promote the activity of mast 
cells, B-cells and certain T-cells.  The major immunobiological effect of IL-10 is the regulation 
of the Th1/Th2 balance.  Th1 cells are involved in cytotoxic T-cell responses whereas Th2 cells 
regulate B-cell activity and function. IL-10 is a promoter of Th2 response by inhibiting IFN-γ 
production from Th1 cells. This effect is mediated via the suppression of IL-12 synthesis in 
accessory cells. IL-10 is involved in assisting against intestinal parasitic infection, local 
mucosal infection by costimulating the proliferation and differentiation of B-cells. Its indirect 
effects also include the neutralization of bacterial toxins (Borish and Steinke, 2003). IL-10 is a 
potent inhibitor of IL-1, IL-6, IL-10 itself, IL-12, IL-18, CSF and TNF-α. It not only inhibits 
the production of proinflammatory mediators but also augments the production of anti-
inflammatory factors including soluble TNF-α receptors and IL-1ra. 
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CYTOKINES THAT MEDIATE AND REGULATE ACQUIRED IMMUNITY 
IL-4 
In addition to T-helper lymphocytes, IL- 4 is derived from eosinophils, basophils, and possibly 
mast cells. In both eosinophils and mast cells, IL-4 exists as a preformed, granule-associated 
peptide and can be rapidly released in allergic inflammatory responses.  
IL-4 stimulates MHC class II molecules, B7, CD40, surface IgM, and low-affinity IgE receptor 
(CD23) expression by B-cells, thereby enhancing the antigen-presenting capacity of B-cells.  
IL-4 induces the immunoglobulin isotype switch from IgM to IgE (Romagnani, 1990).  
Other B-cell–activating cytokines, such as IL-2, IL-5, IL-6, and IL-9, synergize with IL-4 to 
increase the secretion of IgE. IL-4 has been identified in the serum, bronchoalveolar lavage 
fluid, and lung tissue of asthmatic subjects, in nasal polyp tissue, and in the nasal mucosa of 
subjects with allergic rhinitis.  
In addition to these effects on B-cells, IL-4 has important influences on T-lymphocyte growth, 
differentiation, and survival, producing important influences on allergic inflammation. As will 
be discussed later, IL-4 drives the initial differentiation of naïve T-helper type 0 (TH0) 
lymphocytes toward a Th2 phenotype.  
IL-4 is also important in maintaining allergic immune responses by preventing apoptosis of T-
lymphocytes (Borish and Steinke, 2003). The production of IL-4 by Th2 lymphocytes renders 
these cells refractory to the anti-inflammatory influences of corticosteroids.  
Other activities of IL-4 include enhancing the expression of MHC molecules and low-affinity 
IgE receptors (CD23) on macrophages. In contrast to these proinflammatory effects on 
monocytes, IL-4 downregulates antibody-dependent cellular cytotoxicity (ADCC), inhibits 
expression of Fc receptors, inhibits their differentiation into macrophages, and downregulates 
production of nitric oxide, IL-1, IL-6, and TNF-α while stimulating production of IL-1ra.   
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IFN-γ 
The most important cytokine responsible for cell-mediated immunity is IFN-γ.  
It is primarily produced by T-helper lymphocytes but is also derived from cytotoxic T cells and 
NK cells. IFN-γ mediates increased MHC class I and II molecule expression.  
IFN-γ stimulates antigen presentation and cytokine production by monocytes and also 
stimulates monocyte effector functions, including adherence, phagocytosis, secretion, the 
respiratory burst, and nitric oxide production. The net result is the accumulation of 
macrophages at the site of cellular immune responses, with their activation into macrophages 
capable of killing intracellular pathogens (Borish and Steinke, 2003). In addition to its effects 
on mononuclear phagocytes, IFN-γ stimulates killing by NK cells and neutrophils. It stimulates 
adherence of granulocytes to endothelial cells through the induction of ICAM-1, an activity 
shared with IL-1 and TNF-α. As with other interferons, IFN-γ inhibits viral replication. As 
discussed later, IFN-γ is an inhibitor of allergic responses through its capacity to inhibit IL-4–
mediated effects (Farrar and Schreiber, 1993). 
TH1/TH2 BALANCE 
Th1 and Th2 cells differ from the virgin T-helper CD4, their profile is influenced by the stimuli 
present in the microenvironment, during the early stages of the immune response. Each of the 
two subpopulations are self-amplifying, blocking the differentiation of the other (Romagnani et 
al., 1994). The differentiation in Th1 is stimulated by intracellular parasites and is characterized 
by the production of IFN-γ; the principal effector function is the defense mediated by 
phagocytes. 
The differentiation in Th2 occurs in response to allergens and to helminths and is characterized 
by the production of IL-4 and IL-5, the main effector function is the response mediated by IgE, 
mast cells and eosinophilis.  
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Th2 cells can behave as suppressor cells, through the production of IL-4 and IL-13, which act 
as antagonists of IFN-γ and block the macrophage activation induced by T-lymphocytes.  
The cytokines produced also limit the possible tissue damage caused by cell-mediated 
responses.  
Th2 cells also mediate certain inflammatory reactions in which predominate eosinophils and 
mast cells, contributing to the elimination of helminths (Borish and Steinke, 2003). 
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CANNABIS EFFECTS ON THE IMMUNE SYSTEM 
The immune system comprises several components, including lymphoid tissue, such as the 
spleen and lymph nodes, the bone marrow and the thymus where lymphocytes and other 
immune cells are made, and circulating lymphocytes. 
Immunity is either innate or acquired. Innate immunity involves immune responses that do not 
require previous sensitization and exposure to foreign substances whereas acquired immunity 
does. 
Actions of macrophages are part of the host’s innate immunity while the responses mediated by 
B- and T-cells are part of the acquired immunity (Berdyshev, 2000). 
Generally, Δ9-THC has a deleterious effect on a variety of immune parameters. 
Many studies in the literature suggested that cannabis use is associated with an increase in the 
incidence of viral infections and allergic symptoms.  
More specific studies were subsequently designed to clarify the Δ9-THC’s action after in vivo 
and in vitro exposure in various human and animal cells. 
MACROPHAGES 
Cannabis use and effects on innate macrophage functions were initially studied in pulmonary 
models by Berdyshev et al. (1998) Alveoli macrophages are the principal immune-effector cells 
in the lung and are primarily responsible for protecting the lung against infectious 
microorganisms, inhaled foreign substances, and tumour cells. Cannabis smoking reduced the 
ability of alveoli macrophages to kills fungi, pathogenic bacteria, and tumour target cells. 
Furthermore, cannabis smoking depressed production of pro-inflammatory cytokines, which are 
important regulators of macrophage function. This cannabis-related decrease in inflammatory 
cytokine production might be a mechanism whereby cannabis smokers are less able to destroy 
fungal and bacteria organisms, as well as tumour cells.  
  
40 
The inability of alveolar macrophages from habitual cannabis smokers without apparent disease 
to destroy fungi, bacteria, and tumour cells, and to release pro-inflammatory cytokines, 
suggests that cannabis might be an immunosuppressant with clinically significant effects on 
host defense. 
Studies by Tashkin et al. (1997) suggested that regular cannabis consumption reduces the 
respiratory immune response to invading organisms. Further, serious invasive fungal infections 
as a result of cannabis contamination have been reported among individuals who are 
immunocompromised, including patients who were infected by AIDS. 
There are reports of effects of cannabinoids in vitro on various macrophage functions including 
cell spreading and phagocytosis, protein expression, cytolysis and antigen presentation 
(Berdyshev, 2000). 
McCoy et al., (1995; 1999) demonstrated that Δ9-THC influenced the ability of macrophages to 
process antigens necessary for the activation of CD4+ T-lymphocytes. 
Sacerdote et al., (2000a) reported that in vivo and in vitro treatment with the synhetic 
cannabinoid CP-55, 940 reduced the spontaneous and stimulated chemotaxis of macrophages in 
the rat and this effect involved both CB1 and CB2 receptors. 
NO generation by macrophages is an obligatory element of cellular attack on bacterial 
pathogens. Δ9-THC suppresses NO production in mouse peritoneal macrophages, but the 
cannabinoid ligand may increase NO production in human monocytic culture (Klein, 1999). 
Chang et al., (2001) also found that Δ9-THC, AEA and 2-AG reduced LPS- induced NO, PGE2 
and IL-6 production in a concentration-dependent manner through CB2 activation.  
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LYMPHOCYTES  
T-cells and B-cells are the major cellular componentes of the adaptative immune response. 
Marijuana is able to suppress immune function, changing the number and function of T-cells 
(Massi et al., 2006). Finding regarding the proliferation response of peripheral blood T-cells 
from marijuana smokers were generally inhibitory although the evidence is sometimes 
conflicting, with T-cell proliferation responses either suppressed or unaffected (Klein, 1999). 
It is seen in fact a measurable inhibitory effect on leukocytes after acute and chronic treatment 
of relatively high doses of cannabinoids in experimental animals, and high concentrations in 
vitro. 
It is also seen that the cell proliferation is not always suppressed, but rather appears to be 
enhanced by low concentrations of cannabinoids or in response to anti CD3 antigen used as a 
mitogen.  
Massi et al. (1998) reported that, following acute treatment of Δ9-THC, in mice in vivo, and 
with doses that induce analgesic effect, there was no alteration in the proliferative response of 
spleen cells to ConA, but after 7 days of treatment, proliferation was found to be markedly 
reduced.  
Furthermore, a few studies have evaluated the Δ9-THC effect on cytotoxic T-lymphocytes 
(CTL), which can lyse and destroy potentially harmful cellular elements in the body. 
Klein and colleagues (1991) demonstrated that after incubation with Δ9-THC the cytolilytic 
activity of murine splenocyte CTL was depressed by about 60%.  
Δ9-THC did not inhibit CTL binding to the target cell but lowered the cytolytic activity 
subsequent to binding. McKallip et al., (2002), based on studies of Klein et al., (1991), 
demonstrated that Δ9-THC administration in vivo in animals, lowered the cytolytic activity 
subsequent to binding on lymphocytes, mediated by a rapid clearance of dead cells by 
phagocytic cells. After exposing C57BL/ 6 mice to 10 mg/kg body-weight Δ9-THC, he isolated 
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lymphocytes from the thymus and spleen, and he detected that levels of Δ9-THC-induced 
apoptosis in T-cells, B-cells and macrophages. 
He has also demonstrated that Δ9-THC induced higher levels of apoptosis in naive 
lymphocytes, when compared with mitogen-activated lymphocytes, because activated cells 
down-regulated the levels of CB2 on their cell surface. Another major function of immune cells 
examined in the context of cannabinoid treatment is antibody formation. Studies in humans and 
animals have examined the levels of serum immunoglobulins after treatment with cannabinoids. 
In chronic marijuana smokers given cigarettes for two months, the levels of IgG and A were not 
different from those of controls, but the IgE appeared significantly increased (Massi et al., 
2006). Still, very little is known about the Δ9-THC effect of prenatal exposure on the 
developing immune system; Lombard et al. (2011) has recently demonstrated that perinatal 
exposition to Δ9-THC, in animals, negatively affects the immune system of offspring, 
potentially compromising its response to infections. In particular, her study has demonstrated 
that animals that have been exposed to Δ9-THC in utero have a lower immune response to HIV 
at 5 weeks of age, with a decreased proliferative response to HIV restimulation in vitro and 
lower HIV-specific antibody titer in the serum.  
Δ9-TETRAHYDROCANNABINOL‘S ACTION ON CYTOKINES 
The regulation of the concerted work of different types of immune cells is controlled by 
cytokines-signalling proteins synthesized and secreted by immune cells upon stimulation. 
Cytokines, together with their membrane-associated and soluble receptors, constitute a complex 
network with positive and negative regulatory roles, which plays a role in the development of 
Th1 and Th2 dependent immune responses (Borish and Steinke, 2003). 
As previously reported, cytokines of acute phase such as IL-1, TNF-α, and IL-6 produced by 
macrophages and other cells are an important part of natural immunity and help to control 
  
43 
resistance to microbes during the early phases of an infection. 
Immune cytokines, on the other hand, such as IL-2, IL-4 and IFN-γ, are produced by activated 
Th cells and help to eliminate microbes from the body by regulating powerful cell-mediated 
and antibody-mediated immune mechanism (Borish and Steinke, 2003). 
An increasing number of publications confirm that Δ9-THC can alter the cytokine production in 
immune cells. 
 The first work on the modulation of cytokine production belongs to Blanchard et al., (1986), 
who demonstrated that cannabinoids caused an inhibition of the production of IFN-γ in 
splenocytes isolated from animals chronically treated with Δ9-THC, after in vitro stimulation 
with the mitogen PHA, ConA and LPS.  
Moreover Δ9-THC and other non-psychotropic drugs as cannabidiol, have been shown to 
induce both a decrease and an increase of the IFN-γ production, according to the concentrations 
used. Low concentrations (e.g, <0,1 µM) of cannabinoids increase the production of IFN-γ, 
whereas high concentrations diminish the production (e.g, 30 µM) (Watzl et al., 1991). 
The Δ9-THC is also able to induce an inhibition on the production of TNF-α in cultures of 
murine peritoneal macrophages as shown by Zheng et al., in 1992. 
Moreover Klein and Friedman (1990) reported that Δ9-THC in the range of 10-30 µM increased 
IL-1 bioactivity in the supernatant of cultured mouse peritoneal macrophages. 
Zhu et al., (1994) showed that this occurred because Δ9-THC alters the processing and release 
of IL-1 rather than cellular production of the protein.  
Also lymphocytes are limited in their proliferation by cannabinoids. Proliferation of these cells 
is regulated, at least in part, by the system IL-2/IL-2 receptor.  
Nakamo et al., (1992) showed that the secretion of IL-2 secretion by lymphocytes was 
modulated by cannabinoids, thus accounting for some of the inhibitory drug effects on the cell 
growth.  
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Using a chronic treatment in vivo, it is confirmed the thesis that Δ9-THC lower in mice levels of 
IFN-γ and IL-2 in splenocytes, and can steer away from the cytokine network in cell-mediated 
immunity, causing a shift towards Th2 humoral response (Massi et al., 1998). 
This reduces host resistance to pathogens such as viruses, bacteria and parasites. 
The unbalance of Th1/Th2 pattern caused by the exposure to cannabinoids is also confirmed in 
human leukocytes, where the Δ9-THC causes a decrease in production of IL-2 and IFN-γ 
accompanied by a decrease in basal levels of mRNA coding for Th1 cytokines while those for 
Th2 cytokines increase (Kertscher and Cohen B, 2002). 
Zhu et al., (2000) examining the effects of Δ9-THC on the host response to a lung tumor 
challenge, found that animals receiving Δ9-THC experienced a more rapid rate of tumor 
growth. Since they found that Δ9-THC augmented the immunosuppressive cytokines IL-10 and 
TGF-β, while IFN-γ was down-regulated at both the tumor site and in the spleens, they 
suggested that Δ9-THC promotes tumor growth by inhibiting anti-tumor activity by a cytokine-
dependent pathway. 
The effects of Δ9-THC and other cannabinoid compounds such as cannabidiol could be 
considered of benefit for some autoimmune and inflammatory diseases, but they seem to be at 
the basis of a worse tumorigenesis, metastasis, and some infections such as HIV besides 
exacerbating allergic responses. 
Whereas the animal and cellular models do not always predict human responses, 
epidemiological studies have been aimed at clarifying the real impact of marijuana smoking on 
the development of opportunistic infections and cancer. In many studies it has been observed a 
more rapid progression from HIV infection to AIDS in marijuana users and, more recently, its 
use was found to be a risk factor for the development of cancer.  
Roth et al., (2002) in order to evaluate whether human immune responses are similar to animal 
and cellular studies, collected T-cells from healthy volunteers.  
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It was found that in in vitro Δ9-THC down-regulated the expression and release of Th1 
cytokines, and altered normal Th1/Th2 balance in a dose-dependent manner.  
The normal host response to an immunologic challenge involves dendritic cells, specialized 
antigen-presenting cells that activate and expand antigen-specific T-cell clones.  
The relative production of IL-12 (Th1) versus IL-10 (Th2) by dendritic cells and relative 
balance of other Th1 Th2 cytokines in the local environment results in differentiation of the 
activated T-cells towards either a Th1 and Th2 phenotype (Massi et al., 2006). 
Roth et al., (2002) studied the effects of an in vitro exposure of dendritic cells to Δ9-THC, and 
found concentrations of IFN-γ reduced of about 50% while IL-4 levels were increased on 
average by 110%, resulting in a shift in Th1/Th2 cytokine balance.  
The shift Th1/Th2 balance seems to be the cause of susceptibility of laboratory animals against 
many pathogens such as viruses, bacteria and parasites, against which normally the response of 
body is supported by Th1 cytokines (Roth et al., 2002). 
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CANNABINOIDS AND HYPOTHALAMIC-PITUITARY-ADRENAL AXIS 
The hypothalamic-pituitary-adrenal (HPA) axis is a complex neuroendocrine system involved 
in an important number of central and peripheral physiological functions, most of them related 
to appropriate adaptation to stressful situation. The corticotrophin-releasing factor (CRF), 
which is produced in the paraventricular nucleus (PVN) of the hypothalamus, represents the 
main driving force controlling HPA axis activation.  
CRF induces the release of adrenocorticotrophic hormone (ACTH) from the anterior pituitary, 
which in turn regulates glucocorticoid production from the adrenal gland. Then, the 
glucocorticoids negatively regulate the release of both CRF and ACTH trough a feedback 
mechanism (Figure 7). 
 
Figure 7 General organisation of the hypotalamic-pituitary-adrenal (HPA) axis and feedback inhibition of HPA axis 
fucntion by glucocorticoids (CORT), ACTH, adrenalcorticotrophic hormone.  
Figure taken from Lightman and Heyman, 2009 
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Activation of the HPA axis is generally beneficial for the organism; however, when the stress 
response is inadeguate or excessive and prolonged, the cost of maintaining homeostasis 
becomes too high and might thus put an individual at the risk of developing illness, including, 
depression, abdonimal obesity, affective disorders and immune diseases. 
The smoking marijuana or administration of Δ9-THC are both known to stimulate ACTH and 
glucocorticoid secretion in humans and experimental animals model. Several studies have 
actually demostrated that the action of exogenous cannabinoids on the HPA axis is dose-
dependent and involves modulation of CB1 receptors.  
In multiple animal studies, acute administration of cannabinoids increased both ACTH and 
glucocorticoids (GC) in a dose-related fashion, an effect that is likely mediated by an increase 
in CRH (Rodriguez de Fonseca et al., 1992).  
Rodents administered potent CB1 agonist HU-210 had marked activation of the HPA axis, but 
at the highest doses, ACTH decreased while GC increased, suggestive of rapid negative feed-
back by GC (Martin-Calderon et al., 1998). However, tolerance to these effects develops 
quickly with chronic administration (Rodriguez de Fonseca et al., 1992). 
Human studies have shown variable effects of marijuana and component cannabinoids on the 
HPA axis. Similar to the effects in animals, increased cortisol levels have been reported after 
acute administration of marijuana (Brown and Dobs, 2002); conflict results were observed in 
human users of Δ9-THC, after chronic oral administration for example abusing foods like 
cookies rich in marjiuana. 
In their review, Brown and Dobs (2002) related that prolonged activation of the HPA axis, for 
marijuana consumption, may induce to a reduction in adrenocortical reserve. 
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OTHER CANNABIS PHYSIOLOGICAL EFFECTS 
CARDIOVASCULAR EFFECTS 
The use of marijuana is associated with serious cardiovascular consequences; Δ9-THC can 
induce tachycardia (Perez-Reyes, 1999) and increase cardiac output with increased cardiac 
work and oxygen demand. 
It can also produce peripheral vasodilation, orthostatic hypotension and reduced platelet 
aggregation. There was no change of mean global cerebral blood flow after smoking cannabis, 
but increases and decreases in several regions (O’Leary et al., 2002). 
Due to the development of tolerance, long-term use can lead to bradycardia.  
Moreover, postural hypotension and fainting may occur. These and other cardiovascular effects 
may carry a risk for individuals with preexisting cardiac disease, and several cases of acute and 
sometimes fatal cardiac incidents have been reported in young cannabis smokers. 
RESPIRATORY EFFECTS 
The smoke from herbal cannabis preparations contains all the same constituents, excluding 
nicotine, as tobacco smoke, including carbon monoxide, bronchial irritants, tumour initiators 
(mutagens), tumour promoters and carcinogens. A single cannabis cigarette contains higher 
concentrations of benzanthracenes and benzpyrenes, both of which are carcinogens, than 
tobacco smoke. It has been estimated that smoking a cannabis cigarette results in approximately 
a five-fold greater increase in carboxyhaemoglobin concentration, a three-fold greater amount 
of tar inhaled and retention in the respiratory tract of one-third more tar than smoking a tobacco 
cigarette (Benson and Bentley 1995; Khalsa, 2007). This is mainly due to the way a cannabis 
joint is smoked, with deep and prolonged inhalation and no filter.  
In addition, cannabis has a higher combustion temperature than tobacco.  
Chronic heavy smoking of marijuana is associated with increased symptoms of chronic 
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bronchitis, coughing, and with impairment of pulmonary function, pulmonary responsiveness 
and bronchial cell characteristics in marijuana-only smokers (Tashkin et al., 1990).  
It has been calculated that smoking 3-4 cannabis cigarettes a day is associated with the same 
evidence of acute and chronic bronchitis and the same degree of damage to the bronchial 
mucosa as 20 or more tobacco cigarettes a day (Khalsa, 2007).  
Tashking and colleagues (1997) reported that marijuana smoking may predispose individuals to 
pulmonary infection, especially patients whose immune system is already compromised by HIV 
infection and/or cancer and related chemoterapy. 
ENDOCRINE EFFECTS 
Marijuana use affects endocrine and reproductive functions as well, since it inhibits the 
secretion of gonadotropins from the pituitary gland and may act directly on the ovary or testis. 
Cannabinoids affect multiple reproductive functions, from hormone secretion to birth of 
offspring (Schuel et al., 2002). Schuel and colleagues (2002) reported that endocannabinoid 
anandamide signaling regulates sperm functions required for fertilization in the human 
reproductive tract and the abuse of marijuana could affect these processes. Chronic 
administration of high doses of Δ9-THC lowers testosterone secretions; impairs semen 
production, motility, viability and disrupts the ovulatory cycle in animals (Bloch, 1983). 
Furthermore, according to Harclerode (1984) Δ9-THC lowers testosterone levels by lowering 
luteinizing hormone and follicle-stimulating hormone.  
Marijuana depresses the levels of prolactin, thyroid function and growth hormone while 
elevating adrenal cortical steroids.  
Chronic exposure of laboratory animals (rats, mice and monkeys) to marijuana altered the 
function of several accessory reproductive organs: reduced testosterone levels leads to reduced 
testicular function and reduced prostate and seminal vesicle weights. 
  
50 
Chronic administration of marijuana also produces testicular degeneration and necrosis in dogs 
(Khalsa, 2007). 
EFFECTS ON CENTRAL NERVOUS SYSTEM 
Numerous studies show that the phytocannabinoids can induce different degrees of damage to 
the cells of CNS. Recent discoveries have shown that just the Δ9-THC is capable of inducing 
the death of the cells with DNA fragmentation in the hippocampus.  
The areas of the brain primarily involved in cognitive functioning include the frontal cortex, 
hippocampus and cerebellum; it was demonstrated by Herkenham and colleagues (1990) that 
the use of cannabis alters the functioning of these brain areas rich in cannabinoid receptors.  
Finally, changes in the activity of the endocannabinoid system during the phases of high 
neuronal plasticity, as the perinatal and adolescence period, can have behavioral consequences 
for long time. 
IMPAIRMENT OF COGNITIVE BEHAVIOUR 
Through studies of performance evaluation and neuropsychological testing in man, the 
cognitive functions found to be more affected by cannabis use are attention, learning and 
memory. Moreover, the executive functions, processing speed and psychomotor speed are also 
impaired. It has also been described that individuals who start using cannabis in early age may 
be more vulnerable to lasting neuropsychological deficits than those who have started to use it 
later (Chadwick et al., 2013). 
Some studies show the appearance of deficit in sustained attention, in the memory, mental 
flexibility and speed of information processing (Wegener and Koch, 2009). 
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CANNABIS AND SCHIZOPHRENIA 
A recent study showed that the use of cannabis represents an important risk factor for the 
development of psychotic disorders especially in adolescence (Chadwick et al., 2013; Rubino 
and Parolaro, 2013). Although a small fraction of teens that use cannabis develop 
schizoaffective disorders, a number of epidemiological studies repeatedly demonstrate elevated 
risk to develop these psychiatric disorders in association with early-life cannabis use. 
Longitudinal studies assessing the relationship between early-life cannabis exposure and 
schizotypal personality disorder demonstrated that early adolescent use increases adulthood 
symptomatology (Page et al., 2007).  
Although it is challenging to model schizophrenia in animals, phenotypes related to this 
disorder may be studied; rats exposed to cannabinoids during adolescence demonstrate 
increased schizoaffective-like phenotypes, such as impaired sensorimotor gating, which, similar 
to humans, results in decreased prepulse inhibition (Wegener and Koch, 2009).  
Since not all cannabis users develop schizophrenia, early cannabis use likely interacts with 
other factors to facilitate the emergence of this disease (Casadio et al., 2011).  
Recent data have shown that the association between early cannabis exposure and vulnerability 
to schizophrenia is related to individual genetics.  
Caspi et al. (2005) demonstrated that the relationship between adolescent cannabis use and 
schizophreniform disorder, as well as the presence of various psychotic symptoms, was 
attributable to the presence of a functional polymorphism in the catechol-O-methyltransferase 
(COMT) gene.  
This enzyme degrades catecholamines, such as dopamine, and this functional variant 
(COMTvaline158) catabolizes this neurotransmitter more rapidly than the methionine allele 
(Lachman et al., 1996).  
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In cannabis users, schizophreniform disorder is predominantly observed in persons with at least 
one copy of the polymorphic COMT gene (Costas et al., 2011). Moreover, clinical laboratory 
experiments show that Δ9-THC’s acute psychotomimetic effects are moderated by this COMT 
SNP with Δ9-THC-induced psychotic-like experiences and cognitive impairments being more 
pronounced in individuals with the valine158 allele. Animal models also confirm a link 
between the genetic disturbance of COMT and developmental cannabis such that adolescent Δ9-
THC exposure in transgenic mice lacking endogenous COMT synergistically impacts behaviors 
relevant to schizophrenia (Henquet et al., 2006).  
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Δ9-THC AND NEUROINFLAMMATION  
The CNS is a complex organ that consists of a diverse group of cell type, including neurons, 
oligodendrocytes, microglia and astrocytes. While astrocytes are the predominant cell type of 
the CNS, microglia are the resident macrophages of the brain and provide the first line of 
defence against injury, assault and /or infection. These myeloid lineage cells play an import role 
also in CNS remodelling and regeneration. The combined cellular functions of astrocytes and 
microglia form the innate immune system of the CNS (Carlisle and Cabral, 2002). 
In the healthy adult brain, resting microglial cells are characterized by a small soma with fine, 
highly ramified branches and low expression of surface antigens. Following brain stress or 
injury, local changes in the extracellular milieu promote a change in the microglial phenotype, 
referred to as microglial activation. 
Once activated, they produce various cytokines including IL-1, IL-6, TNF-α, and express major 
histocompatibility complex classes I and II antigens and the complement receptor, CR3 (Roche 
et al., 2006). 
Several studies have shown that microglia and microglia-derived cells are the major cell types 
responsible for chronic inflammation that participates in Alzheimer’s disease, Parkinson’s 
disease and amyotrophic lateral sclerosis.  Microglial cells also express both the CB1 and CB2 
cannabinoid receptor; using in vitro model, Carlisle and Cabral (2002) have shown that levels 
of CB2 mRNA and protein are modulated differentially in relation to cell activation state. 
The CB2 is not detected in “resting” cells, is present at high levels in “responsive” and 
”primed” cells, and is identified at greatly diminished levels in “fully” activated cells. 
In contrast, CB1 is present in microglia at relatively low levels and is expressed constitutively 
in relation to the cell activation state. 
Recently, it has been proposed that the role of CB2 in immunity in the CNS is primarily anti-
inflammatory (Carrier et al., 2005); this receptor has the potential to serve as a therapeutic 
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target for appropriately designed CB2-specific ligands that could act as anti-inflammatory 
agents in neuropathological processes such as multiple sclerosis (MS). 
Numerous studies are investigating the effects of cannabinoids in neuroinflammation: for 
example, in Theiler’s virus infection of mouse CNS, an animal model for human MS, it was 
showed that the synthetic cannabinoids WIN55, 212-2 and JWH-015 improved neurological 
deficits and reduced microglial activation, MHC class II expression and T-lymphocyte 
infiltration (Arevalo-Martin et al., 2003). Moreover, Roche and colleagues (2006) have recently 
showed, with in vivo treatment in mice, that the cannabinoid receptor agonist, HU210 
attenuated lipopolysaccharide (LPS)-induced increases in IL-1β and TNF-α in rat brain and IL-
1β, TNF-α, IL-6 and IFN-γ in plasma and the involvement of CB1 was suggested as the CB1 
receptor antagonist, SR141716A, attenuates the immunosuppressive effects of HU210 on IL-1β 
(Roche et al., 2006). 
In the present study, we have started to investigate the effects of Δ9-THC chronic treatment on 
the neuroinflammatory component of CNS in animal models of adolescence and adulthood, 
analyzing the basal production of pro and anti-inflammatory cytokines in the hypothalamus and 
in the hippocampus.The hypothalamus is the ventral portion of the diencephalon and includes 
numerous nuclei that activate, control and integrate peripheral autonomic mechanisms, 
endocrine activity, somatic functions such as thermoregulation, sleep, water-salt balance and 
food intake. Moreover, hypothalamus constitutes together with pituitary and adrenal glands, the 
neuroendocrine axis hypothalamic-pituitary-adrenal (HPA), actively involved in the stress 
response. The hippocampus plays an important role in the regulation of the processes of 
learning and memory and also has a lot of importance in the regulation of emotional behavior. 
Furthermore hippocampus participates in relation to HPA axis feedback, inhibiting the release 
of CRH and the subsequent release of ACTH when the corticosterone level in the circulation 
becomes too high.  
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ADOLESCENCE  
Adolescence is the transition period from childhood to adulthood, characterized by increases in 
peer social behavior, risk-taking and novelty-seeking, and develop of many other functions, for 
example cognitive function and immune maturation. Adolescence in humans spans the age of 
10-12 years old to approximately age 24. It includes, but is not defined by puberty. There is no 
specific endpoint of adolescence and adolescent behaviors may persist into the mid twenties 
(Spears, 2000). 
During this time in humans, adolescents obtain the skills and knowledge they need to operate as 
functional adults in society. Animal models such as the rodent also have a defined adolescent 
period. The adolescence period in mouse is generally considered to be at post natal days 28 
(PND 28). Like in humans, the transition to adulthood is not strictly defined. Some adolescent 
traits may remain until PND 55-60. 
However, mice are generally characterized as early adults by PND 65 (Spears, 2000). 
For the purpose of the present studies, adolescents were defined as PND33, and adults were 
defined as PND 80. 
The educational, social and developmental demands upon adolescents are considerable; illicit 
drug use can acutely interfere with the progression of development, and therefore impose limits 
on how well adolescents transit into adulthood. 
In adolesence age increased involvement in social situations, exposure to peer pressure and 
greater risk-taking and novelty-seeking behaviors all contribute to an increased likelihood of 
adolescent drug-taking. Adolescents are more sensitive to the impairing effects of many drugs, 
but less sensitive to the aversive effects. As such, adolescents are more likely to experiment 
with and escalate drug use at a more rapid rate than adults. 
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The purpose of the present thesis is to characterize the differences in adolescent and adult 
immune parameters after exposure to Δ9-THC, the main psychoactive component of the 
commonly used illicit drug marijuana. 
MARIJUANA USE DURING ADOLESCENCE 
Marijuana is the most commonly used illicit drug in the world, third most used overall after the 
legal drugs alchool and tobacco. This use is especially prevalent among adolescents. 
Adolescent use of marijuana may have long-lasting biological consequences.  
Early-onset cannabis use increases the risk of developing schizophrenia (Arseneault et al., 
2002; Fergusson et al., 2003). 
It has been shown that subclinical positive and negative symptoms were more strongly 
associated with first time use before age 16 than after, and was independent of lifetime 
frequency of use (Stefanis et al., 2004). Adolescent cannabis exposure has been shown to also 
affect cognition, in terms of impaired attentional functions (Ehrenreich et al., 1999) and lower 
verbal IQ (Pope et al., 2003).  
In addition, animal studies demonstrated that chronic exposure to cannabinoid in adolescent but 
not in adult rats produce long-lasting memory impairment and increased anxiety (O’Shea et al., 
2004), impaired spatial and non-spatial learning (Cha et al., 2006) as well as impaired prepulse 
inhibition (Schneider and Koch, 2003; Hall, 2006). 
These studies indicate an influence of cannabis exposure in adolescence age on 
neuropsychiatric functioning. Furthermore, adolescence cannabis use has been hypothesized to 
influence the subsequent abuse of other drugs; indeed, several epidemiological studies report 
that early regular use of cannabis increases the risk of initiation of use of other illicit drugs 
(Agrawal et al., 2004), supporting the cannabis gateway hypothesis (see below) of cannabis as a 
steppingstone towards abuse of other drugs. 
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THE CANNABIS GATEWAY HYPOTHESIS 
A very delicate and controversial issue is the discussion whether cannabis may act as a gateway 
drug, and subsequently lead to increase intake of other illicit drug, and subsequently lead to 
increased intake of other illicit drugs. 
The gateway hypothesis, introduced by Kandel in the 1975, proposes the thesis that 
developmental stages can be observed in drug use.  
The sequence normally begins with the use of legal drugs, such as beer and wine, subsequently 
followed by hard liquor and cigarettes and proceeds in some adolescents progressively through 
the use of cannabis products (marijuana or hashish) to other illicit drugs such as 
psychostimulants and heroin (Hall, 2006). 
There is consistent evidence that the use of cannabis almost invariably precedes the use of other 
illicit drugs. Additionally, there seems to be a strong association between early cannabis use 
and other illicit drug use, because cannabis users are more likely to use psychostimulants, 
hallucinogens or opiods than those who have never used cannabis. 
Many population surveys in western societies show that those who started using cannabis at age 
14 or younger had a higher percentage of present illicit drug abuse or dependence than those 
starting at an older age (SAMHSA 2004). It has been argued that the observed associations may 
simply reflect a combination of a genetic predisposition to substance use in general and levels 
of avaibility and access to different drug classes by contact to peer-groups or a social 
environment encouraging drug use and abuse. Therefore, whether or not there is a casual 
relationship between cannabis use and a progression to other illicit drug use is still heavily 
debated and clarification of this contentious issue definitely requires further research. Evidence 
from animal studies indicates that cannabinoids might induce lasting neuronal modulations that 
could alter the perception and/or reinforcing values of other drugs of abuse, independent of 
genetic, social or cultural factors. A recent study demonstrated that chronic Δ9-THC 
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administration during early puberty of male rats enhanced heroin self-administration in 
adulthood and increased pre-proenkephalin mRNA exclusively in the nucleus accumbes shell 
(Ellgren et al., 2007). This study indicates that there is a link between pubertal cannabis 
experience and further drug intake.  
Cannabis exposure during young ages might have a priming effect on the brain and render 
cannabis users more susceptible to the effects of other illicit drugs; although strong evidence 
suggests that cannabinoids induce neurobiological alterations in common reward pathways 
during this critical period, these findings do not exclude the possibility that other factors such as 
genetic predisposition, social structure and environment might influence these 
neurodevelopmental cannabinoid effects and either enhance or attenuate further progression 
into illicit drugs use (Rubino et al., 2012). 
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AIMS OF THE PROJECT  
The main aim of this study is to investigate whether the use of cannabis in adolescent age may 
have effects on the immune system that can persist over time, even in adulthood, altering the 
susceptibility of the individual to infections, allergic and autoimmune diseases. 
The project is conducted using Balb C/J male mice as an experimental model. 
The use of experimental models allows a better control of the study variables and to investigate 
the effects of the interaction between the consumption of cannabis in adolescent age and the 
immune system, independently of external factors (cultural, social and moral) that would be 
instead be present in a study conducted in human subjects. 
Adolescent and adult mice are treated with increasing doses of Δ9-THC for 10 days. 
Some study groups are sacrificed immediately at the end of treatment, while other study groups 
treated with Δ9-THC in adolescence or in adulthood are left undisturbed for 47 days and 
sacrificed respectively at 90 PND and 137 PND. 
In order to study the long-term effects of Δ9-THC on the immune system the following 
parameters are investigated: 
• The macrophage activation analyzing the profile of pro and anti-inflammatory cytokines 
• The ability of lymphocytes to produce Th1/Th2cytokines  
• The ability to develop an antibody response to a protein antigen 
In order to understand whether the Δ9-THC effects might be due to an alteration of circulating 
hormones, we also assessed the alteration of HPA axis activity, after subacute and chronic Δ9-
THC treatment, by measuring the corticosterone plasma levels in the three study groups. 
In order to identify the mechanisms underlying the long lasting immune effects observed, we 
started to investigate whether they were mediated through modulation of hematopoietic cells. 
We are aware that it is often difficult to translate animal studies to human.  
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This is particularly true for drug of abuse studies, where the route of administration of 
substances in the animals is different from the ones used by humans.  
Therefore we wanted to be certain that Δ9-THC plasma concentrations achieved in mice with 
our experimental protocol would be comparable to those that can be detected in human heavy 
smokers.  
Therefore the blood concentrations of Δ9-THC are verified analyzing the samples with Liquid 
Chromatography-Mass Spectrometry method (LC-MS/MS). 
Since it is now recognized that pro and antinflammatory cytokines play a pivotal role also in 
neuroinflammation, and a few recent evidences seem to indicate that cannabinoids can 
modulate it, we started to study also the effects of Δ9-THC administration in our experimental 
protocol on neuroinflammation, by evaluating the basal production of pro- and anti-
inflammatory cytokines in brain areas that are particularly rich in cannabinoid receptors, such 
as hippocampus and hypotalamus.   
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METHODS 
DRUGS 
Δ9-Tetrahydrocannabinol (Δ9-THC) was obtained from Sigma Aldrich (Milan, Italy) and was 
dissolved in ethanol, cremophor and saline (1:1:18).  
Lipopolysaccaride (LPS) from Escherichia coli and Keyhole Limpet Hemocyanin (KLH) were 
purchased respectively from Sigma-Aldrich (Milan, Italy) and Calbiochem (La Jolla, CA, 
USA). For the Liquid Chromatography/Mass Spectrometry (LC-MS/MS) analysis, methanolic 
stock solutions of Δ9-THC (0.1mg/mL), THC-OH (0.1mg/mL), THC-COOH (1mg/mL) and 
their deuterated analogues THC-D3 (0.1mg/mL), THC-OH-D3 (0.1mg/mL), THC-COOH-D3 
(1mg/mL), used as the internal standards, were purchased from Cerilliant Corporation (Round 
Rock, TX, USA). 
ANIMALS  
Male mice Balb C/J, Post natal days 33 (PND 33) were used as model of adolescence age and 
80 PND were used as model of adult age. The animals were obtained from Charles River 
(Calco, Italy).  All animal experiments were conducted following the guidelines released by the 
Italian Ministry of Health (DL 116/92 and DL111/94-B), and the European Community 
directives regulating animal research (86/609/EEC). All efforts were made to minimize the 
number of animals used and their suffering. 
TREATMENTS 
Animals were housed in a room with controlled temperature (22±1°C), humidity (60±10%) and 
light (12h/day) for at least 1 week before being used. Food and water were available ad libitum. 
The treatment began at 33 PND, for the adolescent model and lasted until 42 PND.  
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During this period, mice received increasing subcutaneous (s.c) doses of Δ9-THC once a day, 
for the following 10 days (5mg/kg 33-35 PND; 10mg/kg 36-38 PND; 15 mg/kg 39-42 PND) or 
its vehicle. For the adult model the treatment began at PND 80, and lasted until PND 89.  
During this period, mice received increasing s.c. doses of Δ9-THC once a day, for the following 
10 days (5mg/kg 80-82 PND; 10mg/kg 83-85 PND; 15 mg/kg 86-89PND) or its vehicle.  
The dose protocol was chosen on the basis of previous experiments from our and other group, 
and the dosage was increased over the ten days in order to counteract a possible development of 
tolerance (Massi et al., 1998; Lombard et al., 2011).  
The treatment schedule is depicted in Figure 8.  
For this study, the mice were divided into 3 main experimental groups: 
1. Adolescent animals  
• Group A mice were treated with subcutaneous injection of vehicle once a day starting 
from 33 PND until 42 PND; at the end of treatment (43 PND) mice were sacrificed to 
assess immune parameters. 
• Group B mice were treated with subcutaneous injection with increasing doses of Δ9-
THC once a day starting from 33 PND until 42 PND; at the end of treatment (43 PND) 
mice were sacrificed to assess immune parameters. 
2. Adult animals  
• Group C mice were treated with subcutaneous injection of vehicle once a day starting 
from 80 PND until 89 PND; at the end of treatment (90 PND) mice were sacrificed to 
assess immune parameters. 
• Group D mice were treated with increasing subcutaneous injections of Δ9-THC once a 
day starting from 80 PND until 89 PND; at the end of treatment (90 PND) mice were 
sacrificed to assess immune parameters.  
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3. Adult animals treated when adolescents  
• Group E mice were treated with subcutaneous injection of vehicle once a day starting 
from 33 PND until 42 PND; at the end of treatment, the mice were housed for 47 days, 
until they reached adulthood (90 PND). At this time, animals were sacrificed to assess 
immune parameters. 
• Group F mice were treated with subcutaneous injection with increasing doses of Δ9-
THC once a day starting from 33 PND until 42 PND; at the end of treatment, the mice 
were housed for 47 days, until they reached adulthood (90 PND). At this time, animals 
were sacrificed to assess immune parameters. 
 
Figure 8 - Treatment schema of three study groups 
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Moreover in order to assess the sub-acute effect of Δ9-THC treatment on corticosterone serum 
levels, a group of adult (83-84 PND) and adolescent  (36-37 PND) mice were treated with 10 
mg/Kg Δ9-THC once daily for two days, and serum obtained 2 hours later the last dose of Δ9-
THC. 
Recently, it has been added a fourth study group, where we started to assess the immune 
parameters, consisting of:  
• Group G mice were treated with subcutaneous injection of vehicle once a day starting 
from 80 PND until 89 PND; at the end of treatment, the mice were housed for 47 days, 
until they reached 137 PND. At this time, animals were sacrificed to assess immune 
parameters. 
• Group H mice were treated with subcutaneous injection with increasing doses of Δ9-
THC once a day starting from 80 PND until 89 PND; at the end of treatment, the mice 
were housed for 47 days, until they reached 137 PND. At this time, animals were 
sacrificed to assess immune parameters. 
 
Figure 9 - Treatment schema of the recent study group 
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MACROPHAGES 
MACROPHAGES PURIFICATION AND STIMULATION 
Mice were inoculated intraperitoneally (i.p.) with 2 ml of 3% Brewer thioglycollate medium 
(Fluka, Sigma-Aldrich, Italy) for macrophage elicitation.  
Four days after thioglycollate treatment, at 43 PND in the adolescent model for the Groups A 
and B, at 90 PND in the adult models for the Groups C, D, E and F, and at 137 PND in the adult 
model for the Groups G and H, mice were sacrificed and macrophages isolated (Martucci et al., 
2007). Briefly, peritoneal elicited cells were harvested in RPMI 1640 medium (Sigma-Aldrich, 
Milan, Italy) plus 10% FCS.  
The viability of the cells was checked by the trypan blue exclusion test.  
The cells were also counted in Turk’s liquid to allow evaluation of nuclei for differential 
counting. Macrophages were resuspended at a concentration of 1 × 106/ml in the same 
harvesting medium and 1 ml/well aliquots were dispensed into 24-well culture plates. Isolation 
and purification of macrophages were carried out by 2 hours of adherence to plastic. As we 
previously demonstrated this procedure produces a population of macrophages with a 
90%purity (Martucci et al., 2007). Non-adherent cells were removed and adherent cells were 
washed twice with PBS solution and incubated with 1µg/ml of LPS for IL-1β, IL-10 and TNF-α 
stimulation. The stimulus was added to the macrophage cultures in a final volume of 1 ml/well 
with RPMI 1640 plus 10% FCS, 1% glutamine, 2% streptomycin solution and 0,1% 2 
Mercaptoethanol (2ME). After 24 hours of culturing the supernatant was removed and collected 
for cytokines evaluation. For mRNA quantification Trizol reagent was added to the adherent 
cells into the plate (see below). The samples were stored frozen at -80°C for subsequent 
analysis. 
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SPLEEN CELLS  
KLH IMMUNISATION AND COLLECTION OF SPLENOCYTES 
Mice were inoculated intraperitoneally (i.p.) with 100 µg of the protein antigen KLH in a 
volume of 0.2 ml of saline; 10 days after immunisation, the animals were sacrificed and their 
spleens were aseptically removed; 20-Gauge sterile needles were used to tease the cells through 
an incision made in the spleen cuticle (Martucci et al., 2007; Sacerdote et al., 2000b).  
The cells were plated at a concentration of 7 × 106 in 24-well plates containing a final 
concentration of 80 µg/ml KLH in a total volume of 1 ml.  
The presence of in vitro KLH restimulates the KLH-specificT-lymphocyte clones previously 
activated by in vivo KLH. This is a frequently used method for inducing cytokine production by 
specific T-lymphocyte clones. 
The plates were incubated at 37°C in 5% CO2 and 95% air, and the supernatants were collected 
after 48 hours (in the case of IFN-γ) or 72 hours (in the case of IL-10 and IL-4), which are the 
times of maximum cytokine release (Sacerdote et al., 2000b); the supernatants were stored at -
80°C for cytokine analysis.  
The KLH concentration used in vitro was chosen on the basis of previous experiments showing 
that it induces sub-maximal but easily measurable cytokine production. 
Times of in vivo immunisation with KLH correspond respectively to 33 PND and to 80 PND in 
adolescence and adult age models (Groups A, B, C and D). In the groups of adult animals 
treated when adolescent and in adult mice evaluated 47days after the end of treatment, KLH 
was administered 10 days before the animal sacrifice, corresponding respectively at 80 and 127 
PND (Figure 8; Figure 9). 
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SERUM COLLECTION FOR ANTI-KLH AB AND CORTICOSTERONE 
EVALUATION  
Ten days after KLH immunisation mice were sacrificed by decapitation at 10.30 AM. Blood 
was collected in tubes and left to clot at room temperature for 8 hours and centrifuged at 
6000×g for 10 minutes. Serum was stored at −20 °C until assayed for Anti-KLH Ab.  
In order to measure corticosterone levels, blood was collected at the end of 10 days treatment 
from adolescent and adult mice, and from adult mice treated as adolescent. Moreover in order 
to assess the sub-acute effect of Δ9-THC treatment on corticosterone serum levels, a group of 
adult (83-84 PND) and adolescent (36-37 PND) mice were treated with 10 mg/Kg Δ9-THC for 
two days, and serum obtained 2 hours after the last administration of Δ9-THC. 
anti-KLH Ab ELISA 
The anti-keyhole-limpet hemocyanin antibody titer (Anti-KLH Ab) was measured in each study 
group with Enzyme-Linked Immunosorbent Assay (ELISA). The plates were coated overnight 
with 10 KLH in a carbonate coating buffer, pH 9.6. Mice sera were diluted 1:25, 1:75 and 1:225 
in PBS/Tween containing 1M NaCl and incubated for 3 hours at 37°C. Alkaline phosphate-
conjugated goat antimouse IgM [µ-chain-specific (Sigma-Aldrich), diluted 1:6000 in 
PBS/Tween] was then added and plates were incubated overnight at 4 °C. After washing, p-
nitrophenyl-phosphate substrate at 1 mg/ml in carbonate buffer was added, and the colored 
product formed was measured at OD 405 nm. 
CORTICOSTERONE EVALUATION 
Corticosterone was measured with a commercially available ELISA kit (IBL International 
GmbH, Hamburg, and Germany) (see below).  
Sensitivity of the method for Corticosterone evaluation was 5 nmol/ L. 
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DETERMINATION OF BLOOD Δ9-THC LEVELS 
In order to estimate Δ9-THC concentrations, together with THC-COOH and THC-OH levels, 
blood was collected from adult and adolescent animals 24 hours after the last Δ9-THC 
administration and from adult mice treated in adolescent age 30, 47 and 60 days after the end of 
treatment (Groups A, B, C, D, E and F). 
The blood collected form each animal was transferred onto Whatman 903 Protein Saver Cards 
(Maidstone, UK) in order to obtain Dried Blood Spots (DBS) samples. DBS samples were 
stored at room temperature in a dark and dry place until the analysis.  
The Dried Blood Spots were then sent to the laboratory of toxico-pharmacological analysis of 
University Alma Mater Studiorum of Bologna, directed by Professor Raggi for Δ9-THC 
analysis and its major metabolites. The Δ9-THC being highly lipophilic has a rather long stay in 
the body. The THC-OH and THC-COOH are the major metabolites of Δ9-THC. The THC-OH 
has psychoactive effects and a short half-life, is quickly transformed into THC-COOH that 
instead has a long half-life and for which no known psychoactive effects have been described. 
The method of Liquid Chromatography and Mass Spectrometry (LC-MS/MS), newly 
developed by the group of Professor Raggi, has a high sensitivity and selectivity and allows to 
evaluate the presence of Δ9-THC and metabolites in the same DBS samples. 
Briefly, 10 mm of the spot are put into a vial in the presence of methanol, centrifuged and the 
supernatant dried. At this dry residue the solvents were then added and the injection of samples 
and standard solutions in HPLC-MS/MS system is performed. 
The LC-MS/MS apparatus was a Waters (Milford, MA, USA) Alliance e2695 system coupled 
to a Waters Micromass Quattro Micro triple quadrupole mass spectrometer. Tandem mass 
spectrometry acquisition was carried out in multiple-reaction-monitoring (MRM) scan mode, 
using an electrospray ionisation source (Mercolini et al., 2013; Mercolini et al., submitted). The 
concentrations of Δ9-THC and its metabolites were expressed as ng/ml. 
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CYTOKINE ELISA 
The levels of IL-1β (R&D Systems, Minneapolis, Minnesota), IL-10, TNF-α, IL-4, and IFN-γ 
(eBioscience, San Diego, California) were determined by Enzyme-Linked-Immunosorbent-
Assay (ELISA) using ultra-sensitive ELISA kit according to the manufacturer’s instruction. 
Sensitivity of the method for IL-1β evaluation was 15,625 pg/ml, for IL-10 was 30 pg/ml, 8 
pg/ml for TNF-α, for IL-4 was 4 pg/ml and 15 pg/ml for IFN-γ.  
Brieflly, a first anti-cytokine monoclonal antibody (Ab-primary) was adhered onto a 
polystyrene plate with U bottom 96 wells. The adhesion of the protein to the plastic polymer 
was favoured by a basic pH and occurs during an over-night incubation at 4 °C.  
Several washings were then carried out so as to eliminate the excess antibody that was not 
bound. The nonspecific sites of the plate were blocked with blocking buffer solution and the 
samples were added. 
The plates were incubated to ensure that any cytokine present in the sample binds to the 
antibody already immobilized to the wells. 
After several washes, the secondary anti-cytokine biotinylated monoclonal antibody is added: 
this binds the immobilized cytokine already linked to primary Ab. Therefore a sandwich was 
formed with the substance in the center and on the sides the antibodies. After another series of 
washes, avidin peroxidase was added which has the task of binding the biotinylated antibody. 
Finally, the enzyme substrate was added: a colored complex is formed of intensity proportional 
to the amount of cytokine present in the sample; the color development was stopped with the 
addition of H2SO4 (2N). 
The result was obtained by reading in a spectrophotometer the absorbance of each well at a 
specific wavelength to each cytokine studied. 
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The amount of cytokine present in each sample is assessed with a calibration curve based on the 
values obtained from the analysis of scalar known concentrations of recombinant cytokine 
together with the samples subjected to ELISA. 
 
Figure 10 - ELISA sandwich 
  
  
73 
RNA EXTRACTION AND REAL-TIME PCR 
Total RNA was extracted by adherent peritoneal macrophages, hypothalamus and hippocampus 
using Trizol reagent (Invitrogen Life Technologies, San Giuliano Milanese, Italy) according to 
the manufacturer’s instructions and re-suspended in 10µl of DEPC-treated water (Fluka).  
After removing DNA contaminations (DNA-free kit, Ambion, Applied Biosystems, Monza, 
Italy) mRNA was quantified and an equal amount of mRNA (1000 ng) underwent to Reverse 
Transcription (iScript Reverse Transcription Supermix, Bio-Rad, Segrate, Italy) to obtain 
cDNA.  
For the process of reverse transcription, in a new series of tubes, for each sample, were added to 
1000 ng of RNA, iScript RT Supermix and finally DEP H20 up to the final volume of 20 µl. 
The tubes were then placed in a thermocycler for 40 minutes as follows: 5 minutes at 25°C 
(Priming), 30 minutes at 42°C (Reverse Transcription) and the last 5 minutes at a temperature 
of 85°C (RT Inactivation).  
The cDNA samples obtained are used for the amplification reaction with Reverse transcriptase-
polymerase chain reaction (Real-Time PCR) using ABI PRISM 7000 (Applied Biosystems, 
Foster City, CA). The reaction was performed in a 25µl volume using Real Master Mix Probe 
Rox (Eppendorf, Milano, Italy). Specific Taqman probes for mouse interleukins IL-1β (Mm 
00434228_m1), IL-10 (Mm00439616_m1), TNF-α (Mm00443258_m1) and for glyceralde-
hydes-3-phosphate dehydrogenase GAPDH (Mm99999915_g1) were purchased from Applied 
Biosystems.  
All PCR assays were done in triplicate, and before starting, we performed a validation 
experiment to demonstrate that the efficiencies of target and reference are similar.  
The reaction conditions were as follows: 95 °C for 2 minutes (initial denaturation), followed by 
40 cycles at 95 °C for 15 seconds (cycled template denaturation) and at 60 °C for 60 seconds 
(annealing and extension); the reaction mixture without the cDNA was used as control.  
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The results were quantified using the comparative threshold method. The Ct value of the 
specific gene of interest was normalized to the Ct value of the endogenous control, GAPDH, 
and the comparative Ct method (2- ΔΔCt) was then applied using adult mice treated with vehicle 
(Group C) as calibrator. 
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EXTRACTION OF HEMATOPOIETIC CELLS 
At the time of sacrifice, the femur of each animal was collected and the bone marrow cells were 
isolated by flushing with RPMI 1640 plus 10% FCS.  
The cells thus obtained were brought to a concentration of 50*106/ml and then were plated and 
incubated for 14 days in medium MethoCult ® (STEMCELL Techonologies, Voden Medical 
Instruments spa, Peschiera Borromeo, Italy) at 37° C and 5% CO2.  
The cells of each mouse were plated in quadruplicated. After 14 days of culture, the total 
number of colonies present for each mouse, in each of 4 wells, was counted by an operator 
unaware of the treatments. It then was made the average of colonies for each group of animals. 
 
Figure 11 - Extraction and counts of hematopoietic cells 
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ASSESSMENT OF BASELINE LEVELS OF CYTOKINES IN THE 
HYPOTHALAMUS AND HIPPOCAMPUS 
At the time of sacrifice the brain of animals were rapidly removed and hypothalamus and 
hippocampus dissected out on an ice- cold plate. The hypothalamus and hippocampus were 
then rapidly frozen on dry ice and stored at -80°C until processing for RNA extraction or 
ELISA cytokine analysis.  
PREPARATION OF THE SAMPLES FOR THE ELISA ASSAY 
Hypothalamus and hippocampus of each animal were sonicated with a sonicator (UP50H 
Compact Lab Homogenizer, Hielscher ultrasonic GmbH; Teltow, Germany) in 225 µl of lysis 
buffer composed as follows: PBS, Complete Mini EDTA-free protease inhibitor cocktail 
(Roche) and EDTA (5 mg/ml). After sonication all samples were centrifuged at 13000 g for 15 
minutes at a temperature of 4 °C.  
A part of the supernatant obtained was used for the protein assay, the remaining part was used 
for the ELISA assay. 
PROTEIN ASSAY OF TOTAL PROTEIN CONTENT IN THE HYPOTHALAMUS AND 
HIPPOCAMPUS 
The protein assay is required to relate the level of cytokine measured by ELISA assay, with the 
amount of total protein present in the samples. 
The protein assay according to Lowry 's method involves the use of bovine serum albumin as 
standard. For the calibration line, bovine serum albumin was prepared at the stock 
concentration of 1 mg/ml in H20d. In each tube we added, in the following order 5, 10, 20, 40, 
60, 80, 100 µl of the stock bovine serum albumin reaching a final volume of 100 µl with 
addition of H20 d. 
200 µl of NaOH 1N and 2ml of Cooper reagent consisting of Na2CO3 2%, CuSO4 ( 5 H2O) 1% 
and Na-K- tartrate 2% ( in H20 d), respectively in the proportion 100:1:1were also added. 
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The samples were incubated avoiding the light and at room temperature for 10 minutes and then 
were added 100 µl of Folin Ciocalteau reagent. 
The tubes were then placed again in the dark for 45 minutes, to finally proceed with the reading 
of the absorbance at a wavelength of 750 nm using a spectrophotometer (Uvicon 941 PLUS, 
Kontron Instrument).  
The controls were obtained by replacing the albumin with 100 µl of H20 d. 
The samples were prepared following an analogous procedure to that used for the standard 
curve, to each tube was added a fixed quantity of sample (15 µl) to which 85 µl of H20 d were 
added to reach the final volume of 100 µl. 
EVALUATION OF BASAL CYTOKINE PRODUCTION WITH ELISA METHOD 
The levels of basal IL-1β, IL-10 and TNF-α cytokine production in hypothalamus and 
hippocampus from Δ9-THC or vehicle treated mice were determined using ultra-sensitive 
ELISA kit according to the manufacturer’s instruction (see paragraph “ CYTOKINE ELISA”). 
Cytokines content were determined by interpolation with standard curves assayed on individual 
plates and normalized to protein content in each tissue. 
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STATISTICAL ANALYSIS  
The results are presented as means ± SEM of values. Statistical analyses were performed using 
one-way ANOVA for parametric results. Follow-up analysis was performed using the Tukey’s 
test for multiple comparisons. In the antibody titers experiments TWO Way ANOVA was 
utilized, with treatment and serum dilutions as factors. Differences were considered significant 
at p < 0.05. 
 
  
 
 
 
RESULTS 
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RESULTS 
MACROPHAGES 
To investigate the effects induced by Δ9-THC treatment on innate immunity, we examined the 
cytokine production by peritoneal macrophages elicitated in vivo with thioglycollate and 
stimulated in vitro with 1 mg/ml LPS. Culture media and macrophages are collected after 24 
hours. Spontaneous production of cytokines was always very low, at the limit of detection, and 
no effect of treatment was ever observed (data not shown).  
Figure 12 shows the effect of chronic Δ9-THC administration on IL-1β, TNF-α and IL-10 
production by peritoneal macrophages obtained from adult and adolescent animals evaluated 
immediately at the end of treatment, from adult mice treated with Δ9-THC when adolescent or 
from adult mice evaluated 47 days after the end of treatment.  
IL-1β, TNF-α and IL-10 are measured as protein concentrations in culture media with ELISA 
method (Figure 12, panels a, b and c).  
Panels a and b shows the results relating to the production of IL-1β and TNF-α in 4 study 
groups; in adolescents and adults mice treated with Δ9-THC, we observe a decrease of pro-
inflammatory cytokines respect to controls:  in agreement with the literature the drug 
administration induces a decrease of inflammatory responses.  
In adult animals treated with Δ9-THC during adolescent period, on the contrary we can observe 
an increase of IL-1β and TNF-α levels in comparison to vehicles, indicating a tendency towards 
a pro-inflammatory state. No significant difference was detected in adult animals evaluated 47 
days after the last administration of Δ9-THC.  
The protein levels of IL-10 after Δ9-THC chronic administration, in the 4 study groups, are 
shown in Figure 12, panel c.  
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This cytokine was increased in young and adult mice treated with Δ9-THC. However in adult 
mice treated in adolescent age and tested at the age of 90 PND, Δ9-THC induced a reversed 
effect: IL-10 concentration decreased in Δ9-THC treated mice. 
Also in this case, no significant difference was detected in adult animals evaluated 47 days after 
the last injection of Δ9-THC.   
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Figure 12 
MACROPHAGES 
 
Figure 12 Effect of chronic Δ9-THC administration on IL-1β, TNF-α and IL-10 production by peritoneal 
macrophages obtained from adult and adolescent animals immediatly at the end of treatment or from adult animals 
treated with Δ9-THC when adolescent and adult mice evaluetd 47 days after the end of treatment. IL-1β, TNF-α and 
IL-10 are measured as protein concentrations in culture media (panels a, b and c). Peritoneal macrophages, elicited 
in vivo by thioglycolate, were stimulated in vitro with 1 mg/ml LPS. Culture media and macrophages are collected 
after 24 hours. (see “ Macrophages purification and stimulation” in Method section for details). 
Values are means ± SEM of 8-10 animals /group 
* p <0.05 vs respective vehicle 
** p <0.01 vs respective vehicle 
*** p <0.001 vs respective vehicle 
a"
b"
c"
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Figure 13 reports the mRNA levels of the pro-inflammatory cytokines IL-1β and TNF-α and of 
the anti-inflammatory cytokine IL-10 (panels a, b and c). 
As shown in panel a, the treatment with Δ9-THC induced a modulation at transcriptional level, 
in fact, the levels of IL-1β mRNA expression were decreased in young and adult mice, 
evalueted immediately at the end of treatment, while they were significantly increased in adult 
animals treated when adolescents. 
In adult animals studied 47 days after the end of treatment, no significant differences were 
found between the two treatments considered. 
Panel b shows the TNF-α mRNA expression in the four study groups. 
The levels of mRNA were significantly decreased by Δ9-THC treatment in young and adult 
mice, evaluated after 10 days of chronic treatment, whereas they were significantly increased in 
adult animals treated in adolescent age with the drug and evaluated 47 days after the end of 
treatment. 
Also in this case, no significant differences were found between the two treatments considered, 
in the fourth study group. We then considered the anti-inflammatory cytokine IL-10 mRNA 
expression (Figure 13, panel c). Also the levels of mRNA expression measured by Real Time –
PCR parallel those of IL-10 protein; treatment with Δ9-THC induced an increase of mRNA 
expression in young and adult mice, while in adult mice treated in adolescent age the drug 
induced a significant decrease of mRNA expression.  
In the fourth study group, no significant differences were found between the two treatments 
considered. 
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Figure 13 
MACROPHAGES 
 
Figure 13 Effect of chronic Δ9-THC administration on IL-1β, TNF-α and IL-10 mRNA levels, determined by Real-
Time PCR, expressed in relation to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and presented as fold of 
increase/decrease relative to vehicle treated animals. 
Values are means ± SEM of 8-10 animals /group 
* p <0.05 vs respective vehicle 
** p <0.01 vs respective vehicle 
a"
b"
c"
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SPLEEN LYMPHOCYTES 
Figure 14 shows the effect of Δ9-THC chronic treatment on the production of T-helper 
cytokines IFN-γ, IL-4 and IL-10 by spleen cells obtained from mice immunized in vivo with 
100 µg of KLH and restimulated in vitro with KLH at concentration of 80 µg/ml . 
The presence of in vitro KLH stimulates the KLH-specific T-lymphocyte clones previously 
activated by in vivo KLH. This is a frequently used method to induce cytokine production by 
specific T-lymphocyte clones (Sacerdote et al., 2000b). 
We report only the data relating to the cytokines production stimulated in vitro with KLH; we 
did not find significant differences in the spontaneous production of cytokines in the four study 
groups (data not shown). The production of the Th1 cytokine IFN-γ appears significantly lower 
in mice treated with Δ9-THC respect to vehicle in all study groups (Figure 14, panel a); in fact 
the levels of this cytokine was significant reduced in adolescent and adult mice at the end of 
treatment with Δ9-THC.  
In animals treated in adolescence age and immunized as adults, the production of IFN-γ 
resulted still significantly lower 47 days after the last administration of the drug. 
We found no difference in the IFN-γ levels, in adult animals evaluated 47 days after the last 
injection of the drug. 
The effects of Δ9-THC on Th2 cytokines IL-4 and IL-10 are reported respectively in panels b 
and c. The response of these cytokines to Δ9-THC chronic treatment appears different from that 
observed with the cytokine Th1. The treatment with the drug induced a significant increase of 
IL-4 and IL-10 production in adolescent and adult mice respect to relative vehicles. However in 
the third study group, we observed a reversed effect, i.e. the production of IL-4 and IL-10 
cytokines is significantly decreased respect to relative vehicle. 
In the fourth study group, as regards the Th2 cytokine levels, no significant differences were 
found between the two treatments considered. 
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Figure 14 
SPLEEN LYMPHOCYTES 
 
Figure 14 Effect of chronic Δ9-THC administration on IFN-γ, IL-4 and IL-10 production by splenocytes obtained 
from adult and adolescent animals evalueted immediately at the end of treatment or from adult animals treated with 
Δ9-THC when adolescents and adult mice evaluated 47 days after the end of treatment. Mice were immunized in vivo 
with KLH 10 days before of the immune parameters evaluation and cells were restimulated in vitro with 80 µg/ml 
KLH for 48 or 72 h (see “ KLH immunisation and collection of splenocytes “ in Method section for details). 
Values are means ± SEM of 8-10 animals /group 
* p <0.05 vs respective vehicle 
** p <0.01 vs respective vehicle 
*** p <0.001 vs respective vehicle 
a"
b"
c"
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IgM anti–KLH 
The titers are reported in Figure 15. The mice were immunized with the antigen protein KLH 
respectively at 33 PND (adolescents) and 80 PND at the beginning of Δ9-THC treatment.  
A third group of animals had received Δ9-THC when adolescent and was immunized at 80 
PND, i.e. 47 days after the last Δ9-THC injection.  
In adolescent and adult animals (Figure 15, panels a and b) the IgM anti-KLH titers measured 
in the sera after 10 days of chronic treatment with Δ9-THC, are significantly reduced compared 
to respective controls. The decrease in the production of the IgM anti–KLH antibodies persists 
in the third study group, 47 days after the last administration of the drug (Figure 15, panel c). 
In the three Δ9-THC groups a low antibody titer than in animals treated with vehicle was 
therefore present, thus demonstrating that these animals were unable to develop an effective 
antibody response. 
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Figure 15  
IgM anti-KLH 
 
Figure 15 Effect of chronic Δ9-THC administration on IgM anti-KLH titers in sera from adult and adolescent 
animals immediately at the end of treatment or from adult animals treated with Δ9-THC as adolescents.  
Adolescents (panel a) and adults (panel b) animals were immunized in vivo with KLH together with Δ9-THC 
treatment, while the third group was treated with Δ9-THC as adolescent and immunized with KLH in adult age, 10 
days before the evaluation of immune parameters (panel c). 
Values are means ± SEM of 8-10 animals /group (Two Way ANOVA) 
** p <0.01 vs respective vehicle 
*** p <0.001 vs respective vehicle 
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CORTICOSTERONE 
In order to evaluate a possible involvement of the HPA axis in the effects that we observed, we 
measured serum corticosterone in mice treated with both acute (10mg/Kg for 2 days) and 
chronic Δ9-THC (10 days treatment).  
As reported in Figure 16, panel a, 2 hours after the last administration of Δ9-THC a significant 
increase of corticosterone levels was present both in adult and adolescent animals. In contrast 
the levels of corticosterone in adolescent and adult animals measured at the end of chronic 
treatment were significantly reduced compared to relative controls.  
The significant decrease in the serum corticosterone levels persists even in the third group of 
study, 47 days from the last administration of the drug (Figure 16, panel b).  
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Figure 16 
CORTICOSTERONE 
 
Figure 16 Effect of Δ9-THC treatment on serum corticosterone levels.  
Panel a: Δ9-THC was administered to adult and adolescent mice at the dose of 10 mg/Kg for 2 days, and serum 
obtained after 2 hours. 
Panel b: Corticosterone levels were measured in adult and adolescent animals at the end of   chronic Δ9-THC 
administration (5mg/Kg for 3 days, 10 mg/Kg for 3 days and 15 mg/Kg for 4 days), and from adult animals treated 
with Δ9-THC when adolescent. 
Values are means± SEM of 6 animals /group 
* p <0.05 vs respective vehicle 
** p <0.01 vs respective vehicle 
*** p <0.001 vs respective vehicle 
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NUMBER OF COLONIES FORMED BY HEMATOPOIETIC CELLS 
Table 1 shows the results relative to the count of the number of colonies formed by 
hematopoietic cells. The cells were obtained from bone marrow taken from the femur from 
adolescent and adult mice of the 3 study groups. The results show no significant differences in 
the number of colonies generated from animals treated with Δ9-THC compared to animals 
treated with vehicle, in none of the three experimental groups considered. 
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Table 1  
NUMBER OF COLONIES FORMED BY HEMATOPOIETIC CELLS 
THC Vehicle 
 
Adolescents 
108,3 ±  12,68 93,33 ±  7,88 
Adults 
99,33 ±  8,33 103,7 ±  1,45 
Adult animals treated whan adolescents 
109,5 ±  6,89 103,7 ±  1,45 
Table 1 Effect of chronic Δ9-THC administration (5mg/Kg for 3 days, 10 mg/Kg for 3 days and 15 mg/Kg for 4 days) 
on the number of colonies formed by hematopoietic cells in adult and adolescent mice evaluated immediately at the 
end of the treatment and adult animals treated with Δ9-TH in adolescent period. 
The bone marrow was obtained from femur of adult and adolescent mice and the isolated cells were cultured in vitro 
for 14 days, for the count of colonies formed. 
Values are means± SEM of 4 animals /group 
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DETERMINATION OF BLOOD Δ9-THC LEVELS 
In order to be sure that Δ9-THC was not present in adult animals treated with the drug during 
adolescence, we measured the levels of Δ9-THC and its major metabolites in blood.  
Table 2 shows the blood levels of Δ9-THC, THC-OH and THC-COOH in adolescent and adult 
animals 24 hours and 30,47, and 60 days after the end of treatment. This work was performed 
in collaboration with the team of Professor Raggi, Università Alma Mater Studiorum, Bologna. 
Δ9-THC is metabolised to 11-hydroxy-Δ9-75-tetrahydrocannabinol (6aR,10aR)-9-
hydroxymethyl-6,6-dimethyl-3-penthyl-6a,7,8,10a76tetrahydrobenzo[c]chromen-1-ol,THC-
OH, by cytochrome P450, subtype 2C977 (CYP2C9). THC-OH is biologically active, since it 
binds CB receptors, and is in turn metabolised by CYP2C9 to 11-nor-9-carboxy-Δ9-
tetrahydrocannabinol(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-79pentyl-
6a,7,8,10atetrahydrobenzo [c]chromen-9-carboxylic acid, THC-COOH. This latter metabolite is 
not psychoactive and has a very long half-life.  
No traces of Δ9-THC or metabolites were found in the blood of mice treated with the vehicle 
(data not shown).  The results indicate that Δ9-THC and THC-COOH were detectable in the 
blood of adolescent and adult mice evaluated after 10 days of chronic treatment, 24 hours after 
the last injection; at 30 days after the end of treatment Δ9-THC was no longer present, but we 
still found  the presence of the non-psychoactive metabolite THC-COOH; 47 and 60 days after 
the end of treatment neither Δ9-THC, nor THC-COOH were detected . 
The presence of the psychoactive metabolite THC-OH was never detected in mice evaluated at 
different time after the end of chronic treatment with the drug. 
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Table 2 
DETERMINATION OF BLOOD CONCENTRATIONS OF Δ9-THC AND ITS METABOLITES LEVELS 
 Adult mice Adolescent mice Mice treated as adolescent 
Blood 
concentrations 
ng/ml 
24 hours after 
last Δ9-THC 
injection 
24 hours after 
last Δ9-THC 
injection 
30 days after 
last Δ9-THC 
injection 
47 days after 
last Δ9-THC 
injection 
60 days after 
last Δ9-THC 
injection 
Δ9-THC 18.47± 2.33 11.63 ± 5.44 <LOD <LOD <LOD 
THC-OH <LOD <LOD <LOD <LOD <LOD 
THC-COOH 15.9 ± 1.38 8.55 ± 4.52 3.7 ± 0.32 <LOD <LOD 
LOD= limit of detection  
Table 2 Presence of Δ9-THC and its metabolites, THC-OH and THC-COOH, in the blood of adult and adolescent 
animals evaluated immediately at the end of the treatment, and of adult animals treated with Δ9-THC when 
adolescent. 
The blood was collected at the end of the treatment (24 hours after the last Δ9-THC injection) and at 30, 47 and 60 
days from the last direct exposure to the drug. 
Values are means± SD of 4 animals /group 
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ASSESSMENT OF BASELINE LEVELS OF CYTOKINES IN THE 
HYPOTHALAMUS AND HIPPOCAMPUS 
We started to study the effects induced by Δ9-THC treatment on basal cytokine production, in 
hyppocampus and hypotalamus. 
Figure 17 reports the concentrations, measured in the two neuronal tissues, of the pro-
inflammatory cytokines IL-1β and TNF-α. 
As shown in panel a, in both the tissues considered, the treatment with Δ9-THC induced a 
significant decrease of IL-1β level in adolescent and adult mice, evaluated immediatly at the 
end of treatment. In contrast, a significant increase of IL-1β concentrations was present in adult 
mice treated as adolescents. 
A similar pattern of modifications is present also when considering the production of TNF-α in 
hyppocampus and hypotalamus (Figure 17, panel b). 
In adolescent and adult mice, evaluated immediatly at the end of treatment, a significant 
decrease of TNF-α concentrationsì was evident in both the neuronal area considered; as 
previously reported for IL-1β, in the third group, i.e. mice treated with Δ9-THC during 
adolescent and studied when they had reached adulthood, the drug induced a reversed effect, 
since TNF-α concentrations appear to be increased 47 days after the end of treatment. 
We then considered the basal production of the anti-inflammatory cytokine IL-10, in the two 
neuronal tissues, hippocampus and hypotalamus; this cytokine was increased in young and 
adult mice treated with Δ9-THC (Figure 18, panel a). 
However in adult mice treated in adolescent age and tested at the age of 90 PND, Δ9-THC 
induced a reversed effect: IL-10 concentration decreased in Δ9-THC treated mice. 
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Figure 17  
 
BASELINE LEVELS OF CYTOKINES  PRODUCTION IN THE HYPOTHALAMUS AND 
HIPPOCAMPUS 
 
Figure 17 Effect of chronic Δ9-THC administration on IL-1β and TNF-α levels of cytokines in the hypothalamus and 
hippocampus obtained from adult and adolescent animals immediately at the end of treatment or from adult animals 
treated with Δ9-THC when adolescent. 
IL-1β and TNF-α are measured as protein, and referred to total protein content. 
Values are means ± SEM of 6 animals /group 
* p<0.05 vs respective vehicle 
** p<0.01 vs respective vehicle 
*** p<0.001 vs respective vehicle 
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Figure 18  
 
BASELINE LEVELS OF CYTOKINES  PRODUCTION IN THE HYPOTHALAMUS AND 
HIPPOCAMPUS 
 
 
Figure 18 Effect of chronic Δ9-THC administration on IL-10 levels of cytokine in the hypothalamus and 
hippocampus obtained from adult and adolescent animals immediately at the end of treatment or from adult animals 
treated with Δ9-THC when adolescent. 
IL-10 is measured as protein, and referred to total protein content. 
Values are means ± SEM of 6 animals /group 
* p<0.05 vs respective vehicle 
** p<0.01 vs respective vehicle 
*** p<0.001 vs respective vehicle 
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DISCUSSION 
Cannabis or Marijuana is the most commonly used drug of abuse worldwide; marijuana use in 
Europe and the U.S. is increasing and the age of drug intake has very early onset and continues 
to fall. In the U.S. it is estimated that 46% of the population has tried marijuana at least once, 
while more than 5% use it continuously. 
The cannabis intake begins very early, around 12 years and the percentage of patients who take 
it gradually increases up to 19 years of age. In Europe it is estimated that more than 23 million 
people have used cannabis, with an average of 7%; in Italy, more than 11% of the population 
appears to be involved. In Italy the use is particularly high among young people between 14 and 
25 years of age (SAMSHA, 2004). 
The immunosuppressive and anti-inflammatory properties of cannabis, including, Δ9-THC have 
been well studied (Berdyshev, 2000; Klein, 2005; Massi et al., 2006); Δ9-THC is known to 
cause immune suppression by various mechanisms including induction of apoptosis in effector 
T-cells, suppressing the inflammatory cytokine production, as well as arresting cell 
proliferation (McKallip et al., 2002; Klein and Cabral, 2006). 
Furthermore, Δ9-THC has been indicated to promote a shift in T-cell differentiation from Th1 
to Th2 (Klein, 2005).  
The immune modulating ability of cannabinoids suggests that these drugs might be useful as 
therapeutics in immune diseases and indeed their efficacy has been tested in several disease 
models (Mackie, 2006).  
In contrast to these potentially beneficial properties, studies on the effects of marijuana 
smoking and cannabinoid unwanted effects, have evolved into the discovery that they can 
decrease host resistance to bacterial, protozoan and viral infection in experimental animal 
models and in vitro systems.  
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Recent immune epidemiological studies suggest that marijuana may also influence the outcome 
of viral infections in humans as well as it can increase the incidence of cancer in humans and 
mice, influencing the immune system as whole (Kaushik et al., 2011). 
Marijuana remains the most commonly used drug of abuse worldwide (Berdyshev, 2000), 
especially by adolescents who are the main consumers of this drug. 
In addition, the habit to attending large groups of peers and an attitude toward sex are often not 
aware/protected, predisposes young cannabis users to be more susceptible to bacterial and viral 
infection. Currently, in the literature there are studies indicating as Δ9-THC intake during 
adolescence is able to influence the brain maturation and may modulate the behavior, emotion, 
affectivity and the incidence of psychiatric disorders in adulthood (Rubino et al., 2008; Realini 
et al., 2009; Tomasiewick et al., 2012) however there are no studies that assess this aspect in the 
immune system. 
The aim of my thesis work was to study the effect on immune responses of Δ9-THC intake in 
adolescent mice, demonstrating both short and long term immune dysfunctions.  
The adolescence is a gradual period of transition from childhood to adulthood (Spear and 
Brake, 1983): this period in humans can be considered as the age range between 12 to 18 years. 
It is very difficult to identify in laboratory animals the period corresponding to the phase of 
human adolescence, such as some researchers have argued that adolescence is uniquely human 
and hence cannot be modeled in animals. However Spear and colleagues, (Spear and Brake, 
1983; Odell, 1990; Spear, 2000) on the basis of behavioural and biochemical specific changes, 
have spotted in the period 28-42 post natal days (PND) a phase comparable to adolescence in 
human.  
Starting from these premises, most of the works that analyzed the Δ9-THC induced 
neurobehavioral modifications in adolescent, were performed using 30-32 PND mice (Rubino 
et al., 2008; Rubino et al., 2012).  
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In our experiments we followed this indication and started the Δ9-THC treatment at 33 PND for 
10 days, in order to have a Δ9-THC exposure time covering the whole adolescence.  
Our experimental protocol included the use of s.c. Δ9-THC treatment or vehicle, for 10 days, 
with increasing doses of  drug, as low as 5 mg/kg until to 15 mg/kg.  
We previously conducted studies using a higher dose of Δ9-THC (starting from 5 mg/kg until to 
25 mg/kg) in the treatment of 10 days, getting a modulation of immune parameters similar to 
that illustrated in this work (data not shown). However, we have decided to show only the data 
related to Δ9-THC treatment with doses in the range 5-15 mg/kg, because plasma 
concentrations of Δ9-THC detectable at the end of our treatment in mice were comparable to 
those that can be found smoking in humans (Mercolini et al., 2013). 
The first result that emerges from our study is the presence of a similar immunomodulation 
induced by Δ9-THC chronic treatment in adult and adolescent mice. Both macrophage and 
spleen cytokines, evaluated 24 hours after the last Δ9-THC administration, are in fact modulated 
in the same direction in the two age groups. Consistently with what reported in the literature for 
adult animals, we observed a clear decrease of macrophage pro-inflammatory cytokines IL-1β 
and TNF-α and increase in the anti-inflammatory cytokine IL-10 (Massi et al., 2006).  
It is well known that several cytokines, and IL-1β in particular, are regulated at several post-
transcriptional and post-translational levels (Ferrari et al., 2007), and previous studies suggested 
that Δ9-THC could affect only secretion of pro-inflammatory cytokines but not transcription 
(Zheng and Specter, 1996). For these reasons, we measured both the released protein and the 
mRNA levels.  The results obtained well correlate the cytokine mRNA and protein, suggesting 
that our Δ9-THC treatment paradigm affects both gene expression and protein production.  
In agreement with the data present in literature, we also confirm the ability of Δ9-THC to alter 
the balance between the cytokines produced by T-helper subsets, Th1 and Th2, skewing it 
towards Th2 (Massi et al., 1998; Klein et al., 2000; Newton et al., 2004; Mackie, 2006).  
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Both in adult and adolescent animals in fact, at the end of 10 days treatment, we measured low 
levels of IFN-γ and high levels of IL-4. The ratio between these two cytokines is generally 
considered an affordable index of the Th1/Th2 status.  
Moreover also a relevant overexpression of IL-10 production by splenocytes is observed, 
demonstrating that this potent anti-inflammatory cytokine is similarly modulated by Δ9-THC in 
macrophages stimulated with LPS and splenocytes restimulated in vitro with the antigen KLH, 
independently on the stimulus utilized to induce its production. 
We supported the hypothesis that also in the adolescent period Δ9-THC directs the cytokine 
network away from cell-mediated immunity, provoking a shift towards Th2. This would be 
interesting, considering that it might reduce the host’s resistance to certain pathogens such as 
viruses, intracellular bacteria and parasites (Massi et al., 2006).   
In the whole the Δ9-THC exposure during adolescent age, the drug can affect both innate and 
acquired immunity, with higher risk of morbidity for infectious disease.  
This aspect is particularly important considering that adolescents often are exposed to 
dangerous habits that can increase the risk of infections such as unprotected sexual intercourses 
or attending events in very often crowded environments (Wang et al., 2012; Matkins, 2013). 
However, the most interesting and surprising results of our studies are the demonstration that 
marijuana abuse during adolescence may have long-term impact and affect the immune 
responses into adulthood, with lifelong consequences.  
In the same direction, a recent study conducted by Lombard and colleagues (2011) 
demonstrated that perinatal exposure to Δ9-THC in mice, altered the immune function not only 
in the fetus, but also during postnatal life.  
In this study, we showed that 47 days after the last Δ9-THC injection in adolescent mice, a 
profound dysregulation of macrophage and splenocytes cytokine production is still present.  
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Indeed, the alterations that are present in adult animals treated as adolescent go in a different 
direction in comparison to what we and others observed immediately at the end of treatment.  
While in adult and adolescent animals at the end of treatment an anti-inflammatory cytokine 
profile is present, in adult mice treated as adolescent a clear pro-inflammatory macrophage 
phenotype is induced. Also these modifications take place at transcriptional levels, as indicated 
by the observed parallelism between protein and mRNA cytokine concentrations.  
Moreover in the third group of study, we found that both Th1 and Th2 cytokines are now 
significantly decreased, indicating a general dysfunction, rather than a specific Th1/Th2 bias. 
Although the data are not fully completed, the absence of alterations in macrophage and 
splenocytes cytokine production measured in animals that received Δ9-THC as adults and 
evaluated 47 days after the end of treatment, would seem to suggest that the alteration observed 
in the third study group are related to fact that treatment takes place in the adolescent period. 
Several differences between adult and adolescent animals are of course present, that can 
account for the high sensibility of adolescent immune system to cannabis. For example it is 
demonstrated that the HPA endocrine axis is particularly active during this stage of 
development and particularly vulnerable to drugs or environmental stressors (van Leewen et al., 
2011). Since it is well known that an altered pro-inflammatory/anti-inflammatory balance is 
involved in many immune related diseases, in consideration of the high levels of IL-1β and 
TNF-α and low IL-10 that we measured in adult mice treated as adolescents, it can be 
speculated that individuals that abused marijuana in young age might be at higher risk of 
developing autoimmune or chronic inflammatory diseases in adulthood.  
As already reported, the main indication for therapeutic marijuana utilization is just for treating 
autoimmune and inflammatory diseases. Therefore the history of drug abuse of each individual 
should be evaluated before proposing medicinal cannabis use for pathology such as multiple 
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sclerosis or inflammatory bowel diseases (Klein, 2005; Nagarkatti et al., 2009; Pertwee, 2009). 
Moreover the constantly low IFN-γ levels can modulate the ability to fight infectious diseases. 
In our experiments we also measured the IgM anti-KLH titers after primary immunization only, 
i.e 10 days after KLH vaccination. As expected the levels of IgG anti KLH were always 
extremely low and never affected by Δ9-THC treatment (data not shown).  
A significant decrease of serum IgM levels were indeed observed in all treatment groups.  
In adult and adolescent animals, that were injected with KLH in the first day of Δ9-THC 
treatment, the low Th1 response can account for the decreased ability to mount an adequate 
IgM responses, thus confirming previous in vitro and in vivo studies (Aguledo et al., 2008; 
Springs et al., 2008).  
The profound dysfunction in cytokine balance that persists also long time after the end of Δ9-
THC treatment may be at the basis of the altered antibody response that is present when 
animals are immunized without concomitant Δ9-THC treatment.    
However, we know that a detailed analysis of other Ig isotypes would have been of interest, 
considering for example the strict dependency between IgE and IL-4 (Takeda et al., 1996).   
The objective of the Ig studies was to evaluate the impact of Δ9-THC treatment on the ability to 
mount an antibody response rather than analyze in detail the isotype switching. From these 
results we can hypothesize that the ability of the host to mount an efficacious Ig response to 
vaccination is altered both during the Δ9-THC intake as well as long time after its abuse.  
The mechanisms at the basis of the peculiar long-term effects induced by Δ9-THC treatment in 
the adolescent mice still need to be identified. Similar shaping of the immune responses after 
exposure to pollutants or other drugs have been described (Gascon et al., 2013).  
Interestingly cannabinoid receptors are expressed also by hematopoietic precursors in murine 
embryonic stem cells and CB activation can affect also hematopoietic stem cells (Lu et al., 
2006; Jiang et al., 2007).  
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Recently Hedge et al. (2010) has shown that cannabinoid receptor activation leads to massive 
mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties.  
It can be hypothesized that an alteration of hematopoietic cells by Δ9-THC in adolescence 
would affect also in the long term the differentiation and maturation of immune cells.  
In this study, we began to test the hypothesis that Δ9-THC can affects hematopoietic stem cells; 
in this direction, we simply counted the number of colonies formed after plating the cells 
obtained from bone marrow of mice treated with Δ9-THC or vehicle. The preliminary results 
obtained showed no significant differences in the number of colonies formed. 
However, we are aware that further experiments, which differentiate the type of colonies, such 
as myeloid towards lymphoid, and further flow cytometric analysis on the various precursors 
will be needed before reaching a proper conclusion.  
However, a possibility is that Δ9-THC can induce epigenetic modifications on hematopoietic 
cells able to induce long-term changes on the differentiation and maturation of immune cells; 
further analysis, to identify possible epigenetic modifications induced by treatment with the 
drug, should be performed.  Morris and Tomasiewicz (Morris et al., 2011; Tomasiewicz et al., 
2012) have recently suggested, that Δ9-THC abuse in the adolescent mice induces alteration of 
neuronal circuits and to alters brain plasticity, probably through epigenetic regulation of 
neurotransmitter genes. 
The possibility of an epigenetic regulation induced by Δ9-THC for cytokine genes is an exciting 
one. Interestingly an epigenetic regulation of IL-10 gene by another drug of abuse, i.e. 
morphine, has been recently reported (Schwarz et al., 2011).   
A further possibility would be that the observed effects might not be mediated by a direct 
activation of CB receptors on cells of the immune system, but by a general dysregulation of 
neuroendocrine functions.   
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In this study, we reported as acute treatment induces an increase of corticosterone levels, while 
a more prolonged treatment, i.e. 10 days, leads to a significant reduction of corticosterone 
levels in all groups of treatments.  
Once again this effect of Δ9-THC permains for very long time after the last drug administration. 
The relationship between Δ9-THC abuse and HPA axis have been extensively studied, often 
reaching contrasting conclusion (Roche et al., 2006).  
Both stimulation and tonic inhibition of HPA have been associated to CB activation. 
In particular, while acute Δ9-THC administration has been linked to HPA stimulation 
(Schramm-Sapyta et al., 2007; Steiner and Wotjak, 2008), prolonged Δ9-THC exposure seems 
to lead to a lowered HPA responses (Roche et al., 2006; Armario, 2010).  
In agreement with our low corticosterone results, two recent studies in the human stated for 
hypo-activity of the HPA axis in adolescents with early onset of cannabis use leading to 
deficient cortisol reactivity to stressors (Huizink et al., 2006; van Leewen et al., 2011).  
The modified endocrine milieu consequent to Δ9-THC treatment could in part be responsible of 
the long-term immunomodulatory effects. 
Indeed since corticosteroid levels are consistently reduced in all chronic experimental groups of 
studies while the cytokine profile is differently affected throughout the groups, it seems 
difficult to directly correlate Δ9-THC effects on HPA and cytokines.  
The fluctuations that we observe during the 10 days treatment (early increase followed by 
decrease) can account for the effects observed immediately at the end of Δ9-THC treatment. 
However, considering the well known immunomodulating properties of steroids (Visser et al., 
1998; Miyaura and Iwata, 2002), the persistence of low corticosterone levels until adulthood are 
compatible with the pro-inflammatory cytokine pattern that we observe in adult animals treated 
as adolescents. The steroid hormones might therefore be involved in the long-term effects 
induced by Δ9-THC.  
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It is known that Δ9-THC, due to its high lipid solubility, can remain in the body for a rather 
long time. In collaboration with the group of Prof. Raggi, University of Bologna, we measured 
the levels of Δ9-THC and its main metabolites in the blood of animals; Δ9-THC and its 
metabolites measurements have been performed in order to rule out the possibility that in adult 
animals treated with Δ9-THC as adolescents some residual Δ9-THC could still be present, in 
order to be so certain that the immune effects observed were due to a long lasting modulation of 
immune responses. 
In human Δ9-THC plasma levels decrease drastically being metabolised to THC-OH, by 
cytochrome P450, subtype 2C9 (CYP2C9) (Watanabe et al., 2007).  
THC-OH is biologically active and is in turn metabolised by CYP2C9 (Hunault et al., 2008) to 
THC-COOH.  
This latter metabolite is not psychoactive and has a very long half-life (Gustafson et al., 2004). 
The relative concentrations of these three compounds can be considered together as markers of 
the time elapsed after the last cannabis intake. 
Consistently, also in mouse we measured high levels of Δ9-THC and THC-COOH 24 hours 
after the last Δ9-THC injection. Δ9-THC had completely disappeared 30 days after the last 
administration, while lower traces of the long half life metabolite were still present.  
THC-COOH does not bind the classical CB receptors and it is therefore devoid of any 
psychoactive properties (Gustafson et al., 2004). Although it is not known its potential ability to 
modulate immunity we can state that 17 days later, at the time when we evaluated all the 
immune response, neither Δ9-THC nor its metabolite were present. 
From our measurements we can also define that the intermediate metabolite THC-OH has an 
extremely short half-life in the mouse, as we never detected it. 
An other important point that is always addressed when Δ9-THC administration is performed in 
animal models, is how the dosage translates to human equivalent doses.  
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However several recent studies from the group of Nagarkatti et al., (2009), (Lombard et al., 
2001; Pandey et al., 2011), have demonstrated that dosages as high as 50 mg/Kg in mouse reach 
Δ9-THC blood concentrations in the range of pharmacological or recreational dose in humans.   
Moreover we now without doubt can affirm that the dose regimen that we utilized in the mouse 
leads to blood Δ9-THC and THC-COOH concentrations similar to the ones that are achieved in 
blood from human chronic smokers.  
Mercolini et al. (2013), in fact, assessed the presence of these cannabinoids in a cohort of 
marijuana smokers and found plasma levels ranging from 3 to 11 ng/ml for Δ9-THC and from 7 
to 20 ng/ml for THC-COOH, in line with the mean Δ9-THC and THC-COOH concentrations 
that we now detected in the mouse.  
It is now known that, in CNS, cells such as astrocytes and microglia produce pro- and anti-
inflammatory cytokines that play a role in many neurodegenerative diseases (Carrier et al., 
2005). The factors that control and modulate these cytokines are many, for example µ-opioid 
and noradrenergic receptors, and it has recently emerged as the endocannabinoid system also 
appears to be involved (Carlisle and Cabral, 2002). 
In the present study, we have started to investigate the effects of Δ9-THC chronic treatment also 
on the neuroinflammatory component of CNS in our adolescent and adult animals, analyzing 
the production of pro and anti-inflammatory cytokines in the hypothalamus and in the 
hippocampus. These areas have been chosen since they are particularly rich in CB receptors and 
primarily involved in many Δ9-THC central effects (Irving et al., 2002). 
Our data, although preliminary, indicate that chronic administration of Δ9-THC is able to 
induce an anti-inflammatory status in brain of adolescent and adult mice assessed immediately 
at the end of treatment, both in the hypothalamus and in the hippocampus.    
In adult animals, treated with the drug as adolescents, the production of pro-inflammatory 
cytokines, in hypothalamus and in hippocampus, appears to be increased with respect to 
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vehicles, indicating a predisposition to a pro-inflammatory status. It is very interesting to note 
how the modulation exerted by Δ9-THC on the peripheral cytokines is in parallel to that exerted 
on the brain. It could be then hypothesized that the factors that regulate the modulation exerted 
by the drug on the peripheral cytokines, are also able to modulate the cytokine production in the 
brain; we are aware that further studies are needed to identify the modulatory factors involved.  
Interestingly we measured basal levels of cytokines, since neither Lypopolisaccaride or other 
activating stimuli were given to the animals. Therefore the results that we have obtained 
suggest the presence of a tonic regulation of the cannabinoid system on brain cytokines. 
In the present study we did not evaluate the relative involvement of CB1/CB2 receptors in the 
observed effects. Obviously Δ9-THC targets both these receptors as an agonist and our main 
aim was to demonstrate that marijuana abuse during adolescence is endangering the immune 
system/cytokine pattern. Several studies from our and other groups have anyhow demonstrated 
that both receptors are likely to be involved in Δ9-THC induced immunomodulation (Sacerdote 
et al., 2000a; Klein et al., 2000; Lombard et al., 2011; Springs et al., 2008).  
Moreover a third cannabinoid receptor GPR55 has been reported and may account for some of 
the immune effects observed in the relative absence of CB1 or CB2 (Newton and Klein, 2012; 
Ryberg et al., 2007). Further studies in this direction will be conducted by us in the adolescent 
mouse model.  Moreover, the 10 days Δ9-THC treatment that we performed could also 
modulate the receptor sensibility, leading to either down regulation or desensitization, as 
previously observed (Massi et al. 2006; Buchweitz et al., 2007).  
Also this aspect will be taken into consideration in a future project.    
In conclusion the present study demonstrates for the first time that Δ9-THC exposure in 
adolescent can trigger immune alterations that persist into adulthood, time after the last Δ9-THC 
administration.  
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These long term modifications are different from the one observed immediately after the end of 
Δ9-THC intake, suggesting the presence of a proinflammatory cytokine pattern and a general 
blunted Th responses.  
The altered immune system may condition the susceptibility of the host to immune related 
pathologies in adulthood and our observations draw the attention on the fact the history of drug 
abuse of each individual should be evaluated before proposing any immunomodulating therapy.
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